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ABSTRACT 
STATISTICAL ANALYSIS AND DATA MINING OF MEDICARE PATIENTS 
WITH DIABETES 
Xiao Wang 
March 25, 2011 
The purpose of this dissertation is to find ways to decrease Medicare costs and to 
study health outcomes of diabetes patients as well as to investigate the influence of 
Medicare, part D since its introduction in 2006 using the CMS CCW ( Chronic 
Condition Data Warehouse) Data and the MEPS (Medical Expenditure Panel Survey) 
data. 
In this dissertation, we introduce pattern recognition analysis into the study of 
medical characteristics and demographic characteristics of the inpatients who have a 
higher readmission risk. We also broaden the cost-effectiveness analysis by including 
medical resources usage when investigating the effects of Medicare, part D. In addition, 
we apply several statistical linear models such as the generalized linear model and data 
mining techniques such as the neural network model to study the costs and outcomes of 
both inpatients and outpatients with diabetes in Medicare. Moreover, some descriptive 
statistics such as kernel density estimation and survival analysis are also employed. 
One important conclusion from these analyses is that only diseases and procedures, rather 
than age are key factors to inpatients' mortality rate. Another important discovery is that 
IV 
at the influence of Medicare part 0, insulin is the most efficient oral anti-diabetes drug 
treatment and that the drug usage in 2006 is not as stable as that in 2005. We also find 
that the patients who are discharged to home or hospice are more likely to re-enter the 
hospital after discharge within 30 days. Two - way interaction effect analysis 
demonstrates that diabetes complications interact with each other, which makes 
healthcare costs and health outcomes different between a case with one complication and 
a case with two complications. Accordingly, we propose some useful suggestions. For 
instance, as for how to decrease Medicare payments for outpatients with diabetes, we 
suggest that the patients should often monitor their blood glucose level. We also 
recommend that inpatients with diabetes should pay more attention to their kidney 
disease, and use prevention to avoid such diseases to decrease the costs. 
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CHAPTER I 
INTRODUCTION 
As healthcare reform has passed and is now law, Medicare will come under more 
intense scrutiny in the healthcare industry. Diabetes is one of the most common chronic 
condition diseases and the 7th leading cause of death in America. It is necessary to study 
the patients with diabetes in the Medicare insurance program. Although there are many 
researchers who study such patients, few of them investigate those patients from a 
statistical or data mining perspective. That is why we choose statistical analysis and data 
mining of the Medicare beneficiaries with diabetes as the topic of this dissertation. 
The primary purpose of this research is to apply statistical knowledge and data 
mining algorithms to reduce the Medicare expenditures on diabetes beneficiaries, 
improve the health outcomes of patients as well as to investigate the influence of 
Medicare, part D since its introduction in 2006. In this chapter, we will briefly introduce 
the background of this research. First, we will present the objectives of this dissertation. 
Then we will review the previous research about diabetes patients within the Medicare 
population and describe our main contributions. Next, we will make some assumptions 
concerning the Medicare data. Then, we will introduce the basic concepts needed for this 
study, including the types of diabetes and their oral medication treatments, Medicare 
insurance and Medicare reform, the data sources and the medical codes. After we 
introduce the basic statistical methodologies used in this dissertation, we will introduce 
the outline for the rest of the chapters. 
1.1 Basic Objectives of Dissertation 
There are several objectives in this dissertation: 
• To see how to decrease Medicare reimbursements for both inpatients and 
outpatients. We try to find out the most important factors influencing Medicare 
payments through various statistical models and data mining algorithms such as 
the decision tree model; we also utilize multivariate analysis to find the directions 
of the relationships between the important predictors and the costs. In that way, 
we propose strategies to decrease Medicare payments. 
• To see how to improve health care quality and outcomes. How to reduce the 
mortality rate of patients and how to decrease the length of hospitalizations are 
two concerns in this dissertation. We mainly employ various kinds of predictive 
models to analyze how variables such as age, gender, and procedures affect the 
outcomes so that we can provide methods to improve health outcomes. 
• To investigate the influences of the Medicare drug plan since it became effective 
in 2006. We study the impacts through the usage of diabetes medications, the 
cost-effectiveness of the drugs and the medical resources utilization. 
1.2 Literature Review and Main Contributions 
1.2.1 Literature Review 
In most cases, patients with diabetes in the Medicare population are mostly 
studied by medical methods, but occasionally, quantitative methods are also utilized. 
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Traditionally, statistical analysis is applied in three ways: cost analysis, outcomes 
research and the study of the impacts of the implementation of Medicare, Part D. For cost 
analysis, researchers only utilized simple statistical models to analyze the relationship 
between the predictors and the dependent variables, costs. For example, Li et al. r I] 
applied a 2-stage, least-squares model to estimate the effects of the predictor on Medicare 
expenditures. Bhattacharyya et al. [2] employed a general linear regression model to 
identify principal cost drivers among the identified cohort to the managed care system. 
Herrin et al. [3] applied a hierarchical generalized linear model to analyze the relationship 
between the costs and physicians and the general practice for Medicare diabetes patients. 
For outcomes analysis, investigators employed basic statistical methods. For 
instance, Kuo et al. [4] utilized the two-tailed t-test statistics to analyze the trend of care 
practice and outcomes among the Medicare beneficiaries with diabetes. McBean et al. [5] 
applied at-test when measuring the differences between the year 1999 and the year 2001 
in diabetes care. 
In terms of Medicare part D, only a few researchers have touched this topic so far 
and they also used one basic statistical model for data analysis. For instance, Karaca et al. 
[6] applied a multiple regression model to analyze how this drug plan affects the 
beneficiaries' out-of -pocket costs. Another research group represented by Schmittdiel et 
al. [7] used multiple logistic regression models to create adjusted percentages of 
diabetes patients across demographic and health plan characteristics responding to the 
survey questions about the implementation of the Medicare, Part D. 
1.2.2 Main Contributions 
Just as mentioned above, although some researchers performed simple statistical 
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analyses when they studied diabetes patients in Medicare, no one has yet investigated 
those using data mining techniques. In this dissertation, we introduce the data mining 
principles into the study of diabetes patients and make several contributions. 
• Introduce pattern discovery into patients' demographic characteristics and 
diseases characteristics analysis. 
• Apply supervised machine learning, decision trees and neural networks to analyze 
health outcomes. 
• In cost effectiveness analysis, instead of comparing two drugs or two clinical trial 
methods, we compare differences of the two years for the same patients. 
• Introduce the quantitative methods into readmission risk analysis for diabetes 
inpatients in Medicare. 
1.3 Assumptions 
Although we will make different hypotheses for different statistical models, we 
also make some general assumptions in the entire dissertation. 
• In the dissertation, we are only concerned about type II diabetes patients in 
Medicare and when investigating the influence of Medicare, Part 0, the research 
subjects are restricted to those who join in the drug plan. 
• We do not consider the differences in severity of the diseases among the patients, 
and when we compare two years of cases, we assume that the diseases of the same 
patient will not become more severe in time. 
• We also assume that there are no differences in the costs and treatments among 
different geographic regions. 
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• We do not consider the discount rate for the QALY (Quality Adjusted Life Year) 
for different years. 
• When it refers to medications, we only consider the generic drugs and do not 
consider the brand name drugs. 
1.4 Basic Concepts 
1.4.1 Information about Diabetes, Its Types and Its Complications 
Diabetes mellitus, or diabetes, is a group of diseases characterized by high blood 
glucose levels that result from defects in the body's ability to produce or use insulin. It is 
a devastating disease that greatly impacts long-term care and is the i h greatest cause of 
death in the US. In recent years, diabetes has become a serious problem. According to the 
CDC (the Centers for Disease Control and Prevention) [8] 23.6 million children and 
adults had diabetes in the U.S.in 2007, and 12.2 million were over 60 years old. 
There are mainly three types of diabetes [9]. Type I diabetes is usually called 
juvenile diabetes since it is common in children and young adults. The cause for Type I 
diabetes is that the body does not produce insulin. Type II diabetes, the most common 
form of diabetes, occurs either because the body does not produce enough insulin or the 
cells ignore insulin. Another type of diabetes is gestational diabetes, which is common to 
pregnant women. However, this dissertation will only focus on type II diabetes in persons 
65 years of age and older. 
Diabetes can lead to many complications such as heart disease and renal failure, 
high blood pressure and anemia. Statistics carried out by the American Diabetes 
Association [10] showed that the probability of people with diabetes have heart diseases is 
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twice that of people without diabetes. Diabetes is the primary cause of end-stage renal 
disease. The CDC [8] states that approximately 60% to 70% of those with diabetes have 
mild to severe forms of nervous system damage, and severe forms of diabetic nerve 
disease are a major contributing cause of lower-extremity amputations. 
In addition, the co-morbidities often suffered by patients with diabetes can affect 
each other. For example, diabetes is the leading cause of renal failure. The National 
Institute of Diabetes and Digestive and Kidney Diseases study r II] showed that nearly 24 
million people in the United States have diabetes; the Annual Data Report supported by 
the United States Renal Data System [12] illustrated that nearly 180,000 persons are 
suffering renal failure due to diabetes. Diabetic nephropathy likely contributes to the 
development of anemia in diabetes patients. Anemia often develops early in the course of 
chronic kidney disease in patients with diabetes and also contributes to the high incidence 
of cardiovascular disease observed in diabetic patients. 
Each year, it takes a large amount of resources to treat diabetes and its 
complications, including organ dysfunctions and neurological disorders (Table 1.1) [13] . 
According to the American Diabetes Association riO], a total of $174 billion was 
expended on the treatment of diabetes in 2007; among the total medical expenditures 
($116 billion), 23% ($27 billion) was for diabetes care and 50 % ($58 billion) was for 
chronic diabetes-related complications. Therefore, it is fundamental to control diabetes. 
Among all the measures to control diabetes, blood glucose monitoring is the best. 
The Diabetes Control and Complications Trial funded by the National Institutes 
of Health reported in 1993 [14] that intensive glucose control prevents or delays the eye, 
nerve and kidney complications of type I diabetes (as cited in Glucose Control Cuts Risk 
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of Heart Disease in Type I Diabetes); and DCCTIEDIC study illustrated that 
intensive glucose control lowers the risk of heart disease and stroke by about 50 % in 
people with type I diabetes. However, renal failure treatment is expensive, since the 
expenditures for the treatment of this disease account for 30 % of the costs of the 
treatment of diabetes, so it is essential to find and examine the factors that impact renal 
failure in order to reduce the total charges of diabetes treatment. 
Table 1.1 Health Care Expenditures Attributed to Diabetes (in millions of dollars) 
Chronic Complications 
Setting Diabetes Neurological Peripheral Cardio- Renal Ophthalmic General Total 
vascular vascular conditions 
Hospital 1,535 3,115 2,719 20,790 3,285 36 23,473 58 ,344 
Physician ' s 2,899 382 382279 1,004 323 899 3,830 9,897 
Emergency 234 138 43 403 132 II 2,717 3,870 
Hospital 842 75 135 317 87 130 1,321 2,985 
Source: Table 12(Abridged) in Economic Costs of Diabetes in the U.S. in 2007 
Type II diabetes can be treated by oral medications [15]. The sulfonylureas such 
as glyburide, glipizide, and glimepiride are all generic medications, which make them 
inexpensive drugs for the management of Type II diabetes mellitus. Another class of 
medication that has a similar mechanism of action to the sulfonylurea medications is the 
meglintinides, including repaglinide (prandin) and neteglinide (starlix). Another drug 
class is alpha glucosidase inhibitors, such as precose. Metformin, the only biguanide, is 
recommended as a mainstay in therapy in patients with type II diabetes. When the above 
medications become ineffective, insulin should be used alone or combined with other 
drugs. 
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1.4.2 Medicare and Medicare Reform Related to Part D Plan 
Medicare is the voluntary health insurance for people of age 65 or older, under 
age 65 with certain disabilities, and any age with permanent kidney failure (called "End-
Stage Renal Disease"). It is required for any senior citizen on social security. It basically 
consists of four parts, Part A (Hospital Insurance), Part B (Medical Insurance), Part C 
(Medicare Advantage Plans) and Part D (The optional prescription drug program). Part D 
uses competing private plans to provide beneficiaries access to appropriate drug therapies. 
As of January 2008 [16], almost 90 % of Medicare enrollees had their prescription drugs 
covered by the part D plan or other creditable sources. In this dissertation, we will not 
study Medicare Advantage Plans because they are run by commercial insurance 
companies instead of CMS (Centers for Medicare and Medicaid Services). 
As the two acts, the Patient Protection and Affordable Care Act and the Health 
Care and Education Reconciliation Act of 20 I 0 were signed into law; several changes 
with the Medicare insurance program have taken effect since 2010. One of the significant 
changes is about the Medicare, part D coverage gap or 'donut hole' [17]: 
• In 2010, if the beneficiary's expenditures reached the donut hole and enter the gap, 
then slhe received a $250 rebate from Medicare. 
• From 2011 to 2020, if the enrollee's expenditures are in the gap, slhe will get a 
50% discount on the total cost of brand name drugs. 
• Medicare will phase in additional discounts on the cost of both brand name and 
generic drugs. 
• By 2010, the Medicare coverage gap would have been cancelled. Instead of 
paying 100 % of the costs during the gap, the beneficiaries only needed to 
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pay for 25 % of the costs. 
The Medicare drug plan was always a controversial issue since its introduction. 
This time, the amendments to the plan make it again a topic of concern. Instead of 
studying of the influences of cancelling the gap, we will investigate the influences 
regarding the implementation of the drug plan due to limited data information. 
1.4.3 Data Sources 
In this research, we utilize two kinds of data sets. One is the CMS CCW (Chronic 
Condition Data Warehouse) data [18] for the year 2004 and the other is the MEPS 
(Medical Expenditure Panel Survey) data [19] for the years 2005 and 2006. 
The CCW data are collected by CMS and provides researchers with Medicare 
beneficiary, claims, and assessment data linked by beneficiary across the continuum of 
care. Between the years 1999 to 2004, it covers a random 5% of the Medicare 
beneficiary population each year. In this research, we use three data files for the year 
2004, outpatienCbase_claims with 2,030,078 records and inpatients_base_claims with 
244,299 items. Since both of them do not cover demography information, the dataset, 
beneficiary _summary _file is needed. 
The MEPS data, collected by the Agency for Healthcare Research and Quality, 
is a class of survey data sets containing such information about medical services and 
employers across the United States. In order to compare the differences in 2005 and 
2006, we harness various kinds of data for these two years. They contain such 
information as office-based visits, outpatient visits, inpatients, prescription drugs and the 
full year consolidation. However, such data have some disadvantages. For instance, time 
information is incomplete. 
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1.4.4 Medical Codes 
Medical codes are very useful tools in medical billing and reimbursement. In this 
study, we will use HCPCS (Healthcare Common Procedure Coding System) codes [20], 
CPT (Current Procedural Terminology) codes [21] and ICD -9-CM (International 
Classification Diagnosis, Clinical Modification, 9th edition) codes [22]. 
HCPCS codes are utilized by CMS for explaining the claims for payments. There 
are two levels of HCPCS codes. Level I is comprised of CPT and Level II is a 
standardized coding system that is used primarily to identify products, supplies, and 
services not included in the CPT. 
CPT codes are numbers used to represent medical procedures and services under 
public and private health insurance programs. CPT codes are developed, maintained and 
copyrighted by the AMA (American Medical Association). As the practice of health care 
changes, new codes are developed for new services, current codes may be revised, and 
old, unused codes are discarded. 
ICD- 9-CM is an official system of codes used to stand for the diagnoses and 
procedures associated with hospital utilization. Those codes are overseen and modified 
by NCHS (the National Center for Health Statistics) and CMS. This system contains two 
kinds of codes; one code is for the diagnosis of diseases and the other is for diagnostic, 
surgical or therapeutic procedures. The common diagnostic ICD9-CM codes for diabetes 
are shown below [23]. 
250.00-250.03 Diabetes mellitus without mention of complication 
250.10-250.13 Diabetes with ketoacidosis 
250.20-250.23 Diabetes with hyperosmolarity 
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250.30-250.30 Diabetes with other coma 
250.40 -250.43 Diabetes with renal manifestations 
250.50 -250.53 Diabetes with ophthalmic manifestations 
250.60-250.63 Diabetes with neurological manifestations 
250.70-250.73 Diabetes with peripheral circulatory disorders 
250.80-250.83 Diabetes with other specified manifestations 
250.90- 250.93 Diabetes with unspecified complication 
1.5 Basic Statistical Methodology 
In this dissertation, several statistical methods and data mining algorithms are 
utilized. The descriptive statistics such as kernel density estimation are applied to study 
the distribution of the costs. The various kinds of statistical linear models such as the 
general linear model and the generalized linear model are used to examine the 
relationships between the predictors and the costs. Two-way interaction effect analysis is 
used to analyze the influence of one diabetes complication on another complication in 
costs and outcomes. The data mining algorithms such as the decision tree model and the 
neural network model are employed for health outcomes and health quality analyses. The 
survival model is utilized for our diabetes medication study. In addition, other theories 
such as cost-effectiveness analysis in health economics are also utilized in this 
dissertation. 
1.6 Outline 
The rest of the dissertation is organized as follows: Chapter II describes the data 
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processing. Chapters III- IV introduce statistical models and supervised / unsupervised 
machine learning. Chapters V-VI discuss Medicare costs and their influencing factors 
for both inpatients and outpatients with diabetes, outcomes and readmission 
risk factors of diabetic inpatients as well as 2-way interaction effects of diabetes 
complications on costs and outcomes. Chapter VII investigates how the Medicare, Part D 
program affects the usage and the cost effectiveness of diabetes medications. During the 
discussion of our research in chapters V - VII, several theories applied in the study such 
as survival analysis and cost-effectiveness analysis are also introduced. The last chapter 
summarizes the dissertation results and gives the conclusions. 
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CHAPTER II 
DATA PREPARATION AND PROCESSING 
Data preparation and processing is a key to successful analysis and accurate 
results. Before we develop a statistical model or perform data mining analysis, we need to 
preprocess the data to get them ready for study. In this chapter, we will briefly discuss 
what techniques are utilized for data processing; that is, data validation, merging data, 
data reduction, data transformation and some SAS functions used for data processing. 
2.1 Data Validation 
During the data validation (a.k.a. data cleaning), several things needed to be 
checked: whether the information such as the diagnosis code is correct and whether the 
variable type is correct. If some problem exists, then it needs to be dealt with by some 
measure. 
2.1.1 Dealing with Missing Values 
It is very common that there are missing values in a large-size data set or a survey 
data and they are needed to be examined in most cases. There are three ways to process 
missing values: elimination, imputation and substitution. 
1. Elimination 
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Sometimes, if the missing values only account for a small percentage of the 
sample, then they can be deleted without any processing. However, this method may 
result in bias or inaccurate results if too many observations are eliminated. 
2. Imputation 
Imputation [24] is a prevailing approach of manipulating the missing values and 
there are several different methods for imputation according to the types of missing 
values. If the values are missing at random; that is to say, the probability of a missing 
value appearing in one variable is not related to the probability of existing missing values 
in another variable, then the values can be simply eliminated from the sample data. 
However, this method may result in unnecessary elimination. If the values are completely 
missing at random and can be judged in this way that the probability of missing values in 
one variable is unrelated to the value of the variable itself or to values of any other 
variable, then imputation is needed. One way to do this is MCMC (Markov Chain Monte 
Carlo), which creates multiple imputations by using simulations from a Bayesian 
prediction distribution for normal data. 
3. Substitution 
Substitution [25] is another approach of handling missing values. Sometimes, 
according to the characteristics and types of variables, the missing values can be replaced 
with some other values, such as the mode, the median, the mean, the maximum or the 
minimum of the variables. 
4. Our Approach 
In our research, only the third method works to some extent. When we perform 
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survival analysis about diabetes drug usage, considerable information about the day, the 
month and the year of the prescriptions in the MEPS data is missing. Therefore, we deal 
with missing values in this way: according to the rule of prescription of drugs, we set the 
missing values of the variable, DAY to the first day of the month and the missing values 
of the variable, YEAR to the year when the data were collected, but we eliminate an 
observation whose month information is missing. 
2.1.2 SAS Functions for Data Cleaning 
1. Characteristic Functions 
In our study, we utilize SAS characteristic functions to remove trailing blanks 
before and after the nominal variables and to find certain letters in a string. The functions 
[261 that we apply include LEFT, TRIM and TRANSLATE. For example, consider what 
we do using the prescription drugs data. 
/*To replace '_' with a blank in the names, removes the 
trailing blanks from theright-hand side of a variable value 
and left justifies the variable value*/ 
NRXNAME=TRANSLATE(LEFT(TRIM(NRXNAME)), '_',' '); 
LEFT (TRIM(CONCAT[I] )); END; RUN; 
2. Date Functions 
We utilized the MDY function to return a date value from the numeric values for 
month, day and year into a SAS date value. For instance, in our project about prescription 
drugs usage, we use the following code to combine the three variables, DAY, MONTH 
and YEAR into one variable, DATE. 
DATE = MDY (RXMM, RXDD, RXYY); 
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2.2 Merging Data 
None of our data contains all the information we need; therefore, we have to 
merge different data files into one file before our analysis. The tools for merging data are 
SAS Enterprise Guide, the Base SAS data step and SAS SQL. 
2.2.1 SAS Enterprise Guide 
This is a user-interface-design SAS module in which we only need to click some 
buttons, and then we can merge the different data sets together. For example, in the 
project to discuss how to reduce the Medicare reimbursements for outpatients, we click 
Filter and Query->Add table to join columns from revenue and beneficiary data sets to 
generate another new data set containing beneficiary ID, HCPCS codes, total charges, 
and so on. 
2.2.2 Base SAS Data Step 
Base SAS is the most commonly utilized method of merging data among the SAS 
users. We employ it for data combination in several analyses. For instance, in analyzing 
the outcomes of diabetes outpatients, we used the following SAS code: 
PRoe SORT DATA=SASUSER.IPCLUS; BY_CLUSTER_ ; 
PROe SORT DATA= SASUSER.IPTCHDEM; BY _CLUSTER_; 
DATA SASUSER.IPKDETCHDEM; 
MERGE SASUSER.IPCLUSTER SASUSER.IPTCHDEM; BY _CLUSTER_; 
2.2.3 SAS SQL 
SAS SQL has some advantages over the base SAS data step; for one thing, before 
merging the data by their common variables, we do not need to sort each data set by their 
common variables. For another, the names of the common variables in different data sets 
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are not required to be the same. Consider a cost-effectiveness analysis of the diabetes 
medications; for example, we can apply an SQL conditional inner join to merge the data. 
/*Combine the life table and 2006 Medicare part 0 
beneficiary table */ 
PROC SQL; 
CREATE TABLE SASUSER.LE06 AS 
SELECT * 
FROM SASUSER.LIFETABLEl AS LT, 
SASUSER.BCHWLQ06 AS BC 
WHERE LT.AGE=BC.AGE06X; 
QUIT ; 
2.3 Data Reduction 
After we get the different data sets into one data set, we need to reduce the data 
size, if possible. There are several approaches: (1) sampling and partitioning (2) principal 
component analysis (3) factor analysis (4) observations or variables selection. 
2.3.1 Sampling and Partitioning 
1. Sampling 
There are mainly three types of data sampling methods [271: (I) simple random 
sampling (2) stratified random sampling (3) cluster sampling. 
(1) Simple random sampling: A sample is selected in such a way that every possible 
sample of the same size is equally likely to be chosen. We can realize this through 
clicking the Random Sampling button in SAS Enterprise Guide by choosing either the 
number of observations or a percentage of the sample. We can also perform random 
sampling through the SAS SURVEYS ELECT procedure. 
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(2) Stratified random sampling: This sample can be obtained by separating the population 
into mutually exclusive strata, and then drawing simple random samples from each 
stratum. When we discuss the relationships between other diseases and renal failure, we 
need to use this method to guarantee that all the rare occurrence events of renal failure are 
selected in the large data set. We realize this through setting the sample node in 
Enterprise Miner in this way [28]: set sample method to stratify, stratified criterion to 
level based, and level selection to rarest level. 
(3) Cluster sampling: This can be obtained by dividing the data into several groups or 
clusters of elements. When we compare the differences between the different diagnosis 
procedures in Medicare payments, we first cluster the procedures into several groups. 
2. Partitioning 
Before we build a predictive model in SAS Enterprise Miner, we often use the 
Partition node to divide the sample into three smaller data sets: training, validation and 
testing [29]. The training set is used to build a model. The validation data set is utilized to 
ensure a model of good fit while the testing data set is applied for comparison to find an 
optimal model. 
2.3.2 Principal Component Analysis and Factor Analysis 
Although principal component analysis and factor analysis are very popular 
approaches, we apply neither of them in our analyses due to a very large data size. 
Instead, we utilize sampling and clustering to reduce the sample size. 
2.3.3 Observations or Variables Selection 
Sometimes, not all the observations meet our requirements, or some variables 
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have nothing to do with our predicted targets; therefore, we need to select observations or 
variables. One method is to apply the KEEP or DROP statements and the following SAS 
code demonstrates how to use them: 
DATA SASUSER.IPCLUS(KEEP=_CLUSTER __ FREQ_ 
CLUS_DESC) ; 
SET EMST.TEXT_CLUSTER; 
In order to avoid duplicate observations, we can apply NODUPKEY: 
RMSSTD 
PROC SORT DATA=SASUSER.COM06 OUT=SASUSER.NREP06 NODUPKEY; 
BY DUPERSID DATE DATEI DATE2; RUN; 
Another method to select observations (a.k.a. rows in SQL) and variables (a.k.a. columns 
in SQL) is SQL conditional selection: 
/*To sort out the diabetes patients*/ 
PROC SQL; 
CREATE TABLE SASUSER.OBDIA05 AS 
SELECT tl.DUPERSID, tl.OBICDlX, tl.OBICD2X, tl.OBICD3X, 
tl.OBICD4X 
FROM SASUSER.FILTER_FOR_QUERY_FOR_FILTER_FOR_ AS tl 
WHERE tl.OBICDlX = '250' OR tl.OBICD2X = '250' OR 
tl.OBICD3X = '250' OR tl.OBICD4X = '250'; QUIT; 
2.4 Data Transformation 
The dominant method of transformations is the Box-Cox transformation [25], 
which attempts to transform a continuous variable into an almost normal distribution. 
This is achieved by mapping the values using the following set of transformations: 
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{
y A -1 
(A) _I - whenA *- 0 
Yi = A 
10g(Yi )whenA = 0 
(2.1) 
where A is the transformation parameter, and Yi is a continuous variable that needs to be 
transformed. What we use data transformation for is to define dummy variables. 
Sometimes, or defining procedures to new variables, we use 0-1 indicator functions and 
the SAS code is shown below to get the new data shown in Figure 2.1. 
IF(Recode_ICD9 EQ: '25000') 
THEN R25000=1; 
ELSE R25000=0; 
~ fU(IDI$ RftGIlt._11l9tli roUNT ,~ PfRCfNT ,~ R25000 i 
NWWvE I other I 16 100 -iV'flWvE 42731 625 
NWWvE V5861 6.25 
NWWvE other 14 87.5 
NMNvE 42731 6.25 
NWWvE V5861 1 6.25 
NWWvE other 14 875 
·~~~~N~t 0ht! 1.~ 1m 
0lWNvE 2859 6.25 
I/INvWvE 5990 6.25 
IWf'NvE other 14 87.5 
R4019 i R585 i RV5861 
Figure2. 1. Newly-defined Variables 
2.5 Other SAS Functions 
i R2n4 ~ R42731 
Besides what was discussed above, we also apply some base SAS functions to 
process the data sets. For instance, when we want to define a string containing all 
possible diagnosis codes, we use the CATX statement, which concatenates character 
strings, removes leading and trailing blanks, and inserts separators. The code is [26]: 
DIAGNOSIS=CATX(' ',ICD9_DGNS_CDl, ICD9_DGNS_CD2, ICD9_DGNS_CD3 
, ICD9_DGNS_CD4,ICD9_DGNS_CD5,ICD9_DGNS_CD6,ICD9_DGNS_CD7,IC 
D9_DGNS_CD8, ICD9_DGNS_CD9, ICD9_DGNS_CDIO, ICD9_DGNS_CDI 1,ICD 
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9_DGNS_CD12, ICD9_DGNS_CD13, ICD9_DGNS_CD14,ICD9_DGNS_CD 15,IC 
D9_DGNS_CD16) ; 
When we want to convert all the values of a variable into observations, we utilize 
the TRANSPOSE function and the code is shown below [26]: 
PROC TRANSPOSE DATA=SASUSER.SORTMR06 OUT=SASUSER.TRANMR06 
PREFIX=MED_; VAR NRXNAME; BY DUPERSID; RUN; 
If we want to calculate the differences between different dates, we apply the 
DATDIF functions: 
DAYS=DATDIF (SDATE, EDATE, 'ACT/ACT'); 
In this chapter, we briefly discussed our approaches of processing the data and we 
will elaborate them in detail in the later application chapters. The process of data 
preparation contains more contents than what we introduced above. For example, it also 
covers exploratory data analysis such as the sample mean analysis or a frequency count 
study. We also utilize SAS to process the data during our study. Other preprocessing will 
be discussed in later chapters. 
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CHAPTER III 
STATISTICAL LINEAR MODELS 
Statistical models and the statistical methods associated with them are versatile 
and robust. There are mainly two kinds of statistical models, one is the linear model, 
which is simple and widely used and the other is the non-linear model. In spite of the 
availability of highly innovative tools in statistics, the main tool of researchers remains 
the linear model, which involves the simplest and seemingly most restrictive statistical 
properties of independence, normality, constancy of variance and linearity. It can be 
divided into several subgroups. (1) the general linear model, including the general linear 
univariate model (ANOV A), the general linear multivariate model (MANOV A), the 
regression model; (2) the generalized linear model, including the generalized 
univariate/multivariate model; (3) the linear mixed model. The general linear model and 
the logistic regression model can be thought of as special cases of the generalized model. 
3.1 The General Linear Model 
The general linear models are a class of linear models, and they can be 
represented by the general linear regression model and ANOV A (Analysis of Variance). 
As for the regression model, there are three subgroups, the simple linear regression model, 
the multiple linear regression model and the logistic regression model. 
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3.1.1 The Multiple Linear Regression Model 
The regression model [30] is the oldest and most used model. It is also the most 
understood model in terms of performance, mathematics, and diagnostic measures for 
model quality and goodness of fit. The regression model has been applied to a very wide 
range of problems in healthcare, finance or medical fields. 
1. Assumptions 
Understanding of the assumptions of a model is the key to successfully build a 
model. The following are the assumptions for the multiple linear model: 
• The relationship between the response variables and the predictors is linear. 
• 
v .1 
Y2 The response vector y = is mutually independent, and the variance of 
nxl 
Yll 
each element of the vector is cr2, which is fixed and unknown. 
• The parameter vector {3pxl = is fixed and unknown. 
• 
{3,,-1 
£1 
£2 
The elements of the error vector £ = 
lOll 
have the characteristics: (I) The 
elements of the vector are independent from each other and identically distributed. 
(2) The expectation of each element: E(£;) = 0; (3) The variance of each 
element, var(£J = (72, where i=1,2, ... n; (4) cov(£; ,£) = 0 if i "* j. 
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2. Expressions 
The matrix formulation of the linear multiple regression model is shown below 
y = Xf3+£ 
where y, /3, E: are as mentioned above, and the vector X = (I 
is the design matrix and I = (l, 1, ... 1) T. 
3. Model Development 
(3.1) 
In developing the model, predictors and the response variables are chosen and the 
choice of algorithms to be applied is also considered. However, model development 
belongs to the application of the model; we will discuss it in detail when presenting our 
analyses. In the following model theories discussion, we will also postpone a discussion 
of our analyses. 
4. Assumption Diagnostics 
The examination of basic assumptions is a fundamental procedure in building a 
model and it is even more important than developing models themselves. The first thing 
we need to do is to examine whether the model meets the assumptions. If a model does 
not meet the basic requirements, then the model building is a failure. There are several 
criteria that are used to check whether the assumptions are met. 
I. Independence Test 
The primary method of testing the independence of the response variables is the 
Durbin-Watson statistic [31]. The test statistic can be written as: 
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~)ei -eH )2 
d = -'-.i=.....:2'-----___ _ 
(3.2) 
In the above expression, ei = Yi - Yi is the residual of individual i, which is the 
difference of the observed and predicted values of the response variable for individual i. 
The value of d is always between 0 and 4. If d = 2, it indicates that the model meets the 
independence requirement and it also indicates that no autocorrelation exists. 
II. Normality Test 
There are three common measures to examine whether the residuals follow 
normal distributions: (1) S-W (Shapiro - Wilk) test, (2) K-S (Kolmogorov - Smirnov) 
test, (3) A-D (Anderson- Darling) test. 
(1) S - W test [32]: The test can be conducted through a W statistic and it can be 
calculated as follows: 
( fa,xu))' 
W = --,---I =_1 __ --'---
11 
~)Xi _X)2 
i=1 
In the above expression, XI, X2 ... Xn represent a random sample that follows a normal 
distribution; x stands for the mean of the sample; X( 1), •• , X(n) are an ordered sample; 
(3.3) 
aI, ... all are constants generated from the means, variances and co-variances of the order 
statistics of a sample of size n from a normal distribution; to be specific, they can be 
calculated in this way: 
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(3.4) 
where E= (El, .. , En ) T and the E/ s are the expected values of the order statistics of the 
random sample and V is the covariance matrix of the order statistics. Whether the sample 
meets normality can be judged by the value of W. The value of W is between 0 and 1. 
Small values of W indicate that the sample does not follow a normal distribution, while 
the value of close to 1 means normality. 
(2) K-S test [33]: This test can be realized through calculating a D-statistic and the 
process is shown below. 
Test hypothesis: Ho: The sample follows a normal distribution 
Ha: The sample does not follow a normal distribution 
The D-statistic is defined as follows: 
(3.5) 
x 
in which Dn is the largest vertical distance between the distribution function F(x) and the 
empirical distribution function Fn(x); the empirical distribution function is defined as: 
I n 
F,,(x)=-Llx<t 
n i=1 ,_. 
(3.6) 
where the xli;' s are ordered statistics, I <. is an indicator function, and its expression is 
\,_.\ 
shown below: 
1 'f < I - { ( Xi - X X,"" -
o otherwise 
(3.7) 
The criterion of judging whether the sample follows a normal distribution is based on the 
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value of the D-statistic. If the value of D is greater than the critical value, then the sample 
does not follow a normal distribution. 
(3) A- D test [32]: In the Anderson- Darling test, the statistic A is calculated and its 
expression is shown below: 
A2 = - n- S (3.8) 
where F is the cumulative distribution function and the variable S is defined in this way: 
11 2i I 
S = L---[logF(Yi)+log(l-F(YI1+,_i)] 
i~1 n 
(3.9) 
If the value of A is smaller than the critical value, then the sample follows a normal 
distribution. 
If the model's requirements are met, then the fitness of the model is another vital 
thing needed to be checked. 
III. Autocorrelation Diagnostics 
In statistics, the autocorrelation [34] describes the correlation between values of a 
random process at different points in time and it can be defined as in (3.10). 
Autocorrelation of the error terms often occur in time series data. 
R(i, j) = E(xi -J.1)(x j - J.1) 
(Yi(Yj 
In the above expression, if R( i,j) is well defined, then its values should lie in [-1,1]. 
(3.10) 
x, J.1, (Y represent the value, the mean and the standard deviance, and i, j stand for two 
different time points. The measure to examine the existence of the autocorrelation is the 
Durbin-Watson statistic [31]. The basic rule is to compare the values of d to the lower 
level dL.a and the upper level dU,a of the critical values at the significance a. 
27 
IV. Multicollinearity Diagnostics 
Multicollinearity exists when the samples are not independent from each other. 
The statistic, VIF (Variance Inflation Factor) [35], can be employed to test for it. The 
variable VIP can be defined in (3.11). 
1 
VIF=--
l-R~ 
(3.11 ) 
where R2 is the model variance, defined in (3.12), in which n is the sample size (a.k.a. 
the number of observations), k is the number of predictors (a.k.a. the number of 
coefficients) and the expression of I _R2 is tolerance. 
i=i 
R" = __ -,-,-k __ (3.12) 
i=i 
n-k+l 
A high value of VIF indicates the existence of multicollinearity and a value greater than 
10 means a serious problem. 
V. Outlier Diagnostic 
Outlier detection is also an important step to test whether the mode is good or not. 
There are mainly four statistics [351 : (1) Leverage (2) Studentized deleted residual 
(3) Dffits-statistic (4) Cook' D statistic. 
(1) Leverage: It is called the hat diagonal, which is used to detect outliers among the 
predictor variables. If we write a prediction model into matrix form as: 
(3.13) 
and if we use the least squares approach to get the minimizer with respect to coefficients 
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[3, we get /J and then we get the expression of the hat matrix H defined in (3.14). 
(3.14) 
The leverage, hii' is the ith diagonal element of the hat matrix. As a rule of thumb, any 
observation with an h ii that meets the following inequality (3.15) is considered as a 
leverage point and it has the potential to change the model. For a small sample, the 
criterion is changed to an inequality (3.16). 
h>2 k + 1 
II 
n (3.15) 
h >3 k + 1 
II -
(3.16) 
n 
In (3.15) and (3.16), n is the number of response variables and k+l is the number of 
coefficients, [30.fJ1 .... [3k . The observation with the largest hii can be said to have the most 
extreme predictor variables, while the observation with the smallest hii values might be 
said to be the most typical. 
(2) Studentized deleted residual: This residual is another useful tool to detect extreme 
values of the observations and it can be calcuated as the same way for the standardized 
residual (a.k.a. studentized residual), except without considering the /h observation. The 
expression for the residual ti can be written as: 
(3.17) 
where ei is the residual for the i1h observation; MSE(i) is the mean squared error for the 
regression model given that the t" observation is left out; hii is a leverage. If the 
value ti of an observation is greater than 2, then the observation is probably an outlier. 
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(3) Dffits statistic [36]: Although some potential outliers may be detected by the above 
two criteria, they may not affect the model. On the contrary, the DFFITs statistic can find 
the outliers that actually have influence on the model. The statistic can be expressed as: 
I 
DFF =t(~)2 
I I I-h 
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(3.18) 
The observation whose DFFi meets the following inequality will be thought to be 
influential. 
[k+l 
D F F; > 2~ -----;;--n- (3.19) 
Here, k and n have the same meaning as the above. 
(4) Cook' D statistic: This is the most often used criterion for outlier detection. Its 
expression is shown below and the signs in it have the same meaning as above. 
(3.20) 
Typically, if the value of Di is greater than 2, the observation should be investigated. 
Through I - V, we discussed methods and criteria to examine whether the 
assumptions of a model are met and we will utilize them for model diagnostics before 
developing our models. 
5. Model Evaluation [35J 
I. Significance Test 
R2 and Adjusted-R2 are used to study the magnitude of effects. If both the 
predictors and the response variables are continuous variables, then R2 will be a good 
measure to demonstrate that the proportion of the variation in the dependent variable is 
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accounted for by the explanatory variables. The rule is that the value of R2 varies from 0 
to I, and the higher the value, the greater the effect. The definition of R2 is displayed in 
(3.12). Unlike R2, the adjusted R2 (3.21) increases only if the new term improves the 
model more than would be expected by chance and it can be defined as: 
R2 = 1- (1- R2) n -I 
adjusted k 1 n- - (3.21) 
The F- test is often used for a model significance check (a.k.a. overall fit of the model) 
and it can be calculated as: 
k 
F1k,n-k-IJ = -1---""-R--=-2-
n - k-I (3.22) 
II. Goodness Test 
One useful tool to check whether the model is good is the root MSE [37] and it 
can be defined in this way: 
n 
"(V_ yA)2 ~.I I 
RMSE= i=1 
n-2 
(3.23) 
Since the RMSE is a frequently-used measure of the differences between values predicted 
by a model and the values actually observed from the parameter being estimated, the 
smaller the value, the better the model. 
3.1.2 Linear Logistic Regression Model 
The linear logistic regression model is a special case of the general linear 
regression model used when the response variable is dichotomous. Most of its 
characteristics are similar to those of the general regression model; therefore, we will 
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focus on its three unique parts in this section: analysis of the results, rare event and model 
selection. 
1. Expression 
The logistic regression model (a.k.a. logit model) [38] is used for prediction of the 
probability of occurrence of an event by fitting data to a logit function: 
log(-P-) = Po + pT X 
1- P 
where p is the probability and the odds ratio is expressed as: 
odd=~ 
1- P 
2 . Rare Event and Oversample 
(3.24) 
(3.25) 
Rare event: If a target variable appears in a fraction of less than 10% in a large 
data set, then it is a rare occurrence event. For instance, fraud rate and mortality rate are 
two rare events with two values, 0 and 1. 
Although the logistic regression model is a very useful model, there arise some 
problems when the model is applied in rare event data. Gary King et al.(2001) [39] 
demonstrated that the logistic regression model could greatly underestimate the 
probability of a rare occurrence event and they suggested that all the rare target variables 
should be included in the model to fix this problem. 
What Dr. King suggested is an approach of oversampling, in which a data set is 
stratified by the levels of a rare event variable and assigned different sample weights to 
different levels. We can compensate for oversampling in two ways, one method is to use 
the sample node in SAS Enterprise Miner as we mentioned in chapter 2 and another 
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method is to employ the surveyselect procedure in SAS/BASE, which we will discuss in 
chapter 6. 
3. Model Selection 
When developing the model, effect selection is often considered. The purpose of 
the selection is to choose the predictors that are significant to the response variable and 
the criteria for each selection vary from method to method. There are 3 main frequently-
utilized methods: (1) forward selection, (2) backward elimination, (3) stepwise selection. 
(1) Forward selection: In this method, at the beginning, only the intercepts and the first n 
explanatory effects are put into the model; then, another new effect significant at the level 
a is input into the model. The process will continue until all the remaining effects 
that are significant outside the model are imported. The criterion for the selected entry 
is the score X2 statistic defined as: 
(3.26) 
where the Ho: hypothesis is defined as follows; 1= a~~); L is the log likelihood 
function; PHD is the maximum likelihood estimation of the coefficient vector f3 under Ho: 
and HS is the hessian matrix defined in the form: 
a2 f(P) a2 f(P) a2 f(P) 
ap12 ap1ap2 ap1apk 
a2 f(P) a2 f(P) a2 f(P) 
H S = ap1ap2 ap; aP2apk (3.27) 
a2 f(P) a2 f(P) a2 f(P) 
apkapl apnap2 apk2 
In the above expression,f is a real-value function: f (XI ..... X n). 
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(2)Backward elimination: In this method, at the beginning, all the effects are fitted into 
the model; then, at each step, the least significant effect among those staying in the model 
will be removed. The process will not stop until all the remaining effects are significant. 
In this step, the results of the Wald test for individual parameters are examined. 
(3) Stepwise selection: The process of this method is a combination of the above two 
methods. At the beginning, only intercepts and n effects are in the model; then, another 
significant effect will enter into the model in each step. However, during the process, if 
some effect in the model becomes not significant, then it will be eliminated from the 
model. The process will continue until no new effect can be input into the model or no 
existing effect can be eliminated from the model. 
4. Model Convergence 
It is important to check whether the convergence criterion is met. The default 
criterion by SAS is the relative Hessian convergence criterion with tolerance number [40] 
and it can be expressed as follows: 
(3.28) 
where f(fJ) is the function with the k dimensional vector: fJ = [~I J; af(fJ) is the 
fJk afk (fJ) 
gradient (a.k.a. first derivative) of fk ( the objective function at iteration k) ; and Hk is the 
Hessian (a.k.a. second derivative) of the objective function at iteration k. The expression 
of the Hessian for the function f(fJ) is similar to the one shown in (3.27). 
5. Output Analysis 
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I. Model Fit Statistic 
Three criteria can be applied to examine the model fitness [40] (1) -2 Log L (Log 
Likelihood), (2) AIC (Akaike Information), (3) SC (Schwarz Bayesian Information). 
(l) -2 Log L: This is the most popular criterion used in hypothesis tests for nested models. 
In this case, OJm means the weight, f m means the frequency, Pm indicates the estimated 
probability of the event, n is the total number, m is the number of successful events; then 
for the mth event, the expression of the log likelihood for the binary target is: 
(3.29) 
(2) AIC: It is used for the comparison of non- nested models on the same sample and it 
can be calculated as: 
AIC = -2 LogL + 2 [(k -1) + s] (3.30) 
where k means the number of levels of the response variable and s stands for the number 
of input variables. 
(3)SC: It is another adjusted form of -2 Log L. The form of SC is shown below and the 
parameters have the same meaning as before: 
SC= - 2 Log L + «k-l) + s) * log Cf.jj) (3.31) 
II. Analysis of Maximum Likelihood Estimates 
There are two items in the output worthy of notice [401: 
Estimate: It explains how the input variables affect the dependent variable, given that the 
other predictors in the model are held constant. 
95% Wald Confidence Limits: This is the Wald Confidence Interval (CI) of individual 
odds ratio, given the other predictors is in the model. For a given predictor variable with a 
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level of 95% confidence, we say that we are 95% confident that upon repeated trials, 95% 
of the CI's would include the "true" popUlation odds ratio. 
3.2ANOVA 
Analysis of Variance is another popular tool among researchers. There are several 
ways to divide ANOV A into different types. According to the structure of the data, it can 
be divided into balanced and unbalanced ANOV A. According to the number of 
dependent variables, there are ANOVA and MANOV A. According to the number of 
predictors, there are one-way ANOV A (a.k.a. one-factor ANOV A), two-way ANOV A 
(two-factor ANOVA) and multi-factor ANOV A. In our analyses, we only study one 
response variable each time; therefore, we will not consider MANOV A, in which there 
are two or more dependent variables. ANOV A can be thought of as a special case of a 
linear model, and hence, it has many characteristics that a general linear model has. 
Besides, with only a slight exaggeration, a multi-factor analysis is very similar to a two-
way ANOV A. Therefore, in this section, we will focus on the special characteristics of a 
one-way ANOV A and two-way ANOV A. 
3.2.1 One-way ANOV A [41] 
There are two ways of parameterizing ANOV A; one is the cell means model 
while the other is the factor effects model. However, as the former is not as robust as the 
latter one; we only explain the factor effects model in this section. 
1. Assumption 
The basic purpose of a one-factor ANOVA is to compare whether there is a 
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difference between the means of the different groups. The assumptions of one-factor 
ANOV A and two-factor ANOV A are the same: 
• The population distributions should be normal, and have equal means . 
• Variances across all of the levels should be equal. 
2. Model Expression 
Y.=I1+a+£. 
I,j I I.} 
where the notations related will be explained below: 
N: total number of observations 
ni = 1,2, .. .r: number of levels of factor x 
nj =1,2, ... s: number of observations at each level i 
the mean for level i : 
the overall mean /-l : 
j=l 
11 
__ -
i-
nj 
~~Y. L.L. I,J 
i=l j=l 
11=--'-------
N 
the difference between the mean of the sample and the mean of x at level i, 
3. Hypothesis 
Ha: not all the fli are equal 
4. Logic of ANOVA 
(3.32) 
(3.33) 
(3.34) 
There are two important parameters in this analysis. One is the sum of squares, 
and the other is the F test. In this part, the notations have the same meanings as before. 
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(l) Sum of squares: The total sum of squares of the model can be divided into the sum of 
the among-group sum of squares and the within-group sum of squares: 
Among- group sum of squares: SSG = n) i a 2 i (3.35) 
i=1 
o 
n 11 -
Within- group sum of squares: SSE = I I (Yi ,) - (ai + 11)) (3.36) 
i=1 j=1 
111 II, 
Total sum of squares: TSE = I I (Yi ,) - 11)2 = SSG + SSE (3.37) 
i=1 j=1 
(2) F test: The F-test is used for comparisons of the components of the total deviation and 
it can be defined as the ratio MSG/MSE (defined in 3.38 - 3.40) where the p value is the 
area of the tail outside the value given by the ratio. If it is small, then the significance 
level is larger than the p-value and so we can reject the null hypothesis; it indicates that 
the predictors are significant. A large F value indicates that there is more difference 
between groups than within groups. 
F=MSG 
MSE 
3.2.2 Two-way ANOVA [42] 
(3.38) 
(3.39) 
(3.40) 
A multi-factor ANOVA can be represented by the two-factor ANOVA; we will 
discuss the two-way analysis for simplicity. 
1. Hypothesis 
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Main effect of factor A : where (Ji = j1-j1i 
Ha: not all the j1i are equal 
Main effect of factor B: Ho: fLl =fL2 ="'=fL j where pj = j1-j1j 
Ha: not all the j1j are equal 
Interaction effect: where )'i.j = j1-j1j 
Ha: not all the j1(i,)) are equal 
2. Expression 
The expression for two-factor ANOV A is: 
fL) = fL + a + f3, + Y(, ') (I,j 1 I 1,1 (3.41 ) 
3. Sums of Squares 
There are at least four types of sums of squares [40]. 
Type I sums of squares: This type of sums of squares is also called sequential sums of 
squares. It can be computed as the decrease in the error sum of squares when the effect is 
added to a model. Type I sums of squares are appropriate for balanced analyses of 
variance in which the effects are specified in proper order and for trend analysis where 
the powers for the quantitative factor are ordered from lowest to highest in the model 
statement. 
Type II sums of squares: Type II sums of squares can also be calculated by comparing 
the error sums of squares for subset models. It is the reduction in the SSE due to adding 
the effect to a model that contains all other effects except those being tested. 
Type III sums of squares: Type III sums of squares is also referred to as the partial 
sums of squares. Because they do not depend upon the order in which effects are 
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specified in the model, this type is more popular and useful than type I sums of squares. 
They can also be used for unbalanced designs. 
Type IV sums of squares: Type IV sums of squares are used for designs with missing 
cells. The results are not unique. 
3.3 The Generalized Linear Model 
The generalized linear models [431 are a class of linear models that includes the 
Poisson regression model and the gamma model, etc. The model uses a nonlinear link 
function to describe how the mean of a population is related to a linear predictor and 
allows the dependent variable to follow any distribution belonging to the exponential 
family of distributions (including many common distributions such as a normal 
distribution, an exponential distribution, a gamma distribution, etc.). With the 
introduction of GEEs (the generalized estimating equations) by Liang and Zeger [44], the 
correlated data also can be fit into a generalized linear model. Therefore, the generalized 
linear model can be used in more cases than the traditional linear model. 
3.3.1 Assumption 
The generalized linear model still assumes that the relationship between the 
predictors and the response variable is linear. However, it has its own different 
assumptions from the other linear models. 
• The distribution of the dependent variable is not necessarily a normal distribution. 
• The variance of the sample is constant for all observations. 
• The relationship between the mean of a sample and an input variable can be linked 
through a nonlinear link function. 
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3.3.2 Expression 
The linear component of this model is the same as the general linear model. If we 
use Yi to stand for an element of the response vector, J1i for the mean of Yi, 1 for the link 
function, which describes how J1i is related to Yi, V(J1i) is a variance function with respect 
to J1i, and 0" is the variance of Yi , then the expression for the model can be described as 
follows: 
Linear components: v = xTfJ 
- I I 
Link function: r(JlJ = x~ fJ 
Variance function: ()( v) = ¢V (JlJ 
- I 
Wi 
3.3.3 Link Function for Different Distributions 
(3.42) 
(3.43) 
(3.44) 
The link functions vary from distribution to distribution. The differences among 
these link functions are the range and scale of the probabilities they produce. 
1. The General Linear Model 
Distribution: normal: [ ( )
2] 1 1 y-Jl f(y)=--exp -- --
.j2Jr() 2 () 
fore -00,+00) (3.45) 
Link function: identity: Y(Jl) = Jl (3.46) 
2. Logistic Regression 
Distribution: binomial: fer) = (: )Jl 1 (1- Jl)'H, r = O,l,2, ... n (3.47) 
Link function: log itY(Jl) = loge ~) 
1- Jl (3.48) 
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3. Poisson Regression in Log-linear Model 
Distribution: Poisson: 
Link function: 
A,k e-'( 
f(k) = --,k = 0,1,2 ... 
k! 
log Y(j1) = 10g(j1) 
4. Gamma Model with Log Link 
Distribution: gamma fey) = _1 _( yv)V exp(- yv), y E (0,00) 
r(v)y j1 j1 
Link function: log Y(j1) = 10g(j1) 
3.3.4 Output Analysis [38, 41] 
1. Goodness of Fit 
(3.49) 
(3.50) 
(3.51) 
(3.52) 
When evaluating the adequacy of the generalized liner model, one criterion, the 
deviance of the model is often used. The rule is that the deviance is compared with its 
asymptotic l with the same degree of freedom distribution to find the p-value; if the p-
value lies in a certain allowable range, then the model fits the sample well. 
2. Type I analysis & Type III analysis 
One fundamental application of the generalized linear model is to find out all the 
prominent predictors to the dependent variable. The importance of the variables can be 
measured by X2 , which presents the difference in deviances of fitted log likelihoods 
between successive models. In other words, if the value of l for a variable is larger than 
those of the other variables, then this variable is the most important variable to the 
dependent variable. 
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I. Type I Analysis 
One special property of type I analysis is that its results depends on the order by 
which the independent variables are input into the model. The analysis can be run in this 
way such that at the beginning, only an intercept term is input into the model. In 
subsequent steps, one of the additional effects enters into the model. During each step, a 
likelihood ratio statistic is computed between successive pair of models. P-values are 
calculated based on the asymptotic distributions of the likelihood ratio statistics. By 
comparing the corresponding p-value for each variable to a significance level, we can 
judge whether a variable is significant in the model. 
II. Type III Analysis 
A Type III analysis does not depend on the order in which the terms for the model 
are specified. This analysis consists of specifying a model and calculating likelihood ratio 
statistics for type III contrasts for each term in the model. Under this analysis, a 
maximum likelihood statistic is calculated through constrained optimization under the 
condition that the Type III function of the parameters is equal to 0 and can be defined as 
below: 
LR = 2[L(/J) - L(P)] (3.53) 
in which /J is the unconstrained estimate, jJ is the constrained parameter estimate, with 
an asymptotic l distribution under the condition that the Type III function of the 
parameters is equal to 0, with degrees of freedom equal to the number of parameters 
associated with the effect. However, this analysis is time-consuming; it is recommended 
that the researcher reduce the sample size before applying it. 
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3.3.5 The Poisson Regression Model 
The Poisson regression model is another common linear model with a count 
variable as a response variable and it assumes that the dependent variable follows 
a Poisson distribution. 
1. Expression[45] 
The frequently- used expression for the Poisson regression model is: 
log(E(Y) = log(t) + /Y X (3.54) 
where log(t) is an offset. 
2. Adequacy of the model 
After developing a Poisson regression model, adequacy of the model is the first 
thing to check since overdispersion [46]often occurs in a Poisson regression model. 
Overdispersion occurs when there is more variability than a model is expected to have. 
Typically, if the deviance or Pearson's X2, divided by the degrees of freedom, is 
greater than 1, then the model may be overdispersed. 
One approach of adjusting for overdispersion [47] derives from the theory of 
quasi likelihood and the basic idea is as follows: 
• Import a scale parameter <1>, then E(y) = f..l and Var (y) = <1>f..l; if <1> > I, then the 
• 
model is overdispersed. 
<i> = Pearsonz
2 
[45], where N is the number of sample cases and p is the number 
N-p 
of parameters. 
• <1> is unknown, and therefore, under this modification, the frequently-used method 
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called the Fisher-scoring procedure for the estimated covariance matrix is 
changed from (XT WTy 1 (standard error) to <l>(XT WTyl, where W= diag (WI, 
W2, ... WIl ). 
This adjustment will be further discussed later in chapter 6. 
3.4 The Generalized Linear Mixed Model 
The generalized linear mixed model [48] is a statistical model that extends the 
generalized linear model by incorporating a normally distributed random effect [49], 
which is an effect whose levels are assumed to be selected randomly. 
3.4.1 Assumptions 
• The relationship between the exploratory variables and the response variable is 
linear. Otherwise, a non-linear mixed model should be applied. 
• The random effect should follow a normal distribution; otherwise, a hierarchical 
linear mixed model will be employed. 
• The model cannot be used when the data are correlated. 
3.4.2 Expression 
The generalized linear mixed model can be defined in this way: 
y = Xf3+ZY+E (3.55) 
where X and Z are known design matrices, the error E - N(O,R); the random effect y 
-N(O,G), where G, R are variance matrices. The model has the following properties: 
• 1J=Xf3+Zy (3.56) 
is a linear predictor with combined fixed effects and random effects. 
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• E(yly) =r-
1 
(XP + Zy) = f.1 (3.57) 
r-1 (.) is an inverse link function and its selection is typically based on the error 
distribution. 
• Var(y) = G (3.58) 
The variance function is used to model non-systematic variability. 
(3.59) 
where D is a diagonal matrix containing the variance functions and R means "R-side" 
random effect and Var(y / y) is the variance matrix in a model with only R-side random 
components. 
3.4.3 Estimation Method 
In the generalized linear mixed model, most estimation approaches also rest on 
some likelihood principle. To obtain maximum likelihood estimates, we should maximize 
the marginal likelihood shown below: 
t(P, y) = ff(yly)p(y)dy (3.60) 
3.4.4 Output Analysis 
1. Assumptions 
The generalized linear mixed model is a very complicated model and its output 
analysis varies in different sample data. In our later research, we will utilize it for a 
binary response variable, and hence we will focus on the logistic regression with random 
effects. In this case, there are n (=s +t) groups of subjects, two properties (PI. P2 ) and one 
eventy. Suppose that s subjects are randomly selected to have property land t subjects 
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have property 2. The purpose of the model is to compare the occurrence of the event for 
the two properties among different groups. Therefore, the event that a subject is chosen to 
have property 1 or 2 can be counted as fixed effects and the group effects are random 
effects. We define the following terms: 
• nil and ni2 represent the number of subjects reported to have property I or 2 and 
i stands for a group. 
• Pi! and Pi2 stand for the probability of the event occurring to property I or 2. 
and 
and 
• ri is a random effect such that Yillri - B( nil' Pil); Yi21ri - B(ni2 , Pi2). 
Pil _ 
log(--) - flo + fll + ri 
1- Pi! 
10g(1 Pi2 ) = flo + fl2 + Y 
- Pi2 
2. Fitness Evaluation 
(3.61) 
(3.62) 
Whether the model fits the sample can be judged through the fit statistics table, 
which has three criteria, pseudo-likelihood, generalized X2 and generalized l divided by 
its degrees of freedom. We consider the measure, X2 / OF. If its value is very close to I, 
then it indicates that the model fits the sample pretty well. 
3. Random Effects Prediction 
In order to predict the probability of the random effects, two methods are utilized; 
one uses prediction in the whole model, the other only rests on the fixed effects. In this 
procedure, two kinds of predictions of probabilities are generated for each observation 
(take one observation with property I for example) and they are shown below, 
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A I I E(. .) = A A 
Yz! Yz 1+ exp{- Po - p, - rJ (3.63) 
A ) I 
E(YiI = { A A}' 
1+ exp - Po - p, 
(3.64) 
3.5 Comments 
Each linear model discussed here has its own unique characteristics and has 
different applications. The logistic regression model is by far the most popular 
classification model, extending the techniques of the multiple regression model to 
research situations in which the outcome variable is categorical, especially for the target, 
which is a binary variable. However, for a rare occurrence of mortality, adjustments need 
to be made to the model. Analysis of Variance is often applied to compare the means of 
different sample data, no matter whether the sample is balanced or unbalanced. It is 
widely employed in sociology and psychology and so on. The generalized linear model 
extends the applications of the general linear model to a dependent variable following a 
non-normal distribution such as a gamma distribution or a Poison distribution as well as 
to the correlated data. Therefore, it is a popular research tool in the cost analysis, which 
often follows a gamma distribution and longitudinal analysis in the healthcare industry. 
The generalized linear mixed model can be applied for dichotomous, ordinal and nominal 
outcomes as well as ranked data. Therefore, it can be employed for assessing the trends in 
disease rates, modeling counts or predicting the probability of occurrence in time series. 
In this chapter, we briefly introduced the theories and methods related to our 
analyses, most of which are utilized to study one dependent variable. So far, we have 
only discussed cases when there exist linear relationships between the predictors and the 
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response variables. What if the relationship between the exploratory variables and the 
dependent variable is non-linear, or what if there is no specific predicted variable? In 
those cases, we will employ supervised/unsupervised machine learning, which we will 
introduce in the next chapter. 
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CHAPTER IV 
UNSUPERVISED /SUPERVISED MACHINE LEARNING 
Machine learning [50] is a subfield of data mining, and it was conceived in the 
early 1960's with the clear objective to design and develop algorithms and techniques that 
implement various types of learning, mechanisms capable of inducing knowledge from 
examples of data. Machine learning is widely applied to medical diagnosis, bio-
informatics and object recognition in computer vision and so on. According to the causal 
structure of the model, the learning can be divided into two types: 1. unsupervised 
learning, II. supervised learning. Unsupervised machine learning includes: 
• Cluster analysis (e.g. means, hierarchical algorithms) 
• Association rules (a.k.a. market basket analysis) 
• Collaborative filtering 
Supervised machine learning contains: 
• Classification trees (e.g. decision trees) 
• Regression analysis (including the logistic regression) 
• Neural networks 
• K-nearest neighbors 
• Rule induction 
• Support vector machine 
We have already discussed some of the algorithms listed above, such as the 
regression analysis in chapter III, and some of these algorithms we will not use in our 
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research. Therefore, in this section, we will elaborate on cluster analysis, association rule 
analysis, the decision tree model, the neural network model and rule induction. 
4.1 Unsupervised Machine Learning 
In unsupervised learning situations, all observations are assumed to be caused by 
latent variables and there is no distinction between the independent and the dependent 
variables. Although it does not have a target variable, it does have some purposes. 
Unsupervised learning is primarily composed of two techniques: cluster analysis and 
market basket analysis, which are often utilized in consumer market analysis or patients' 
medical conditions analysis. 
4.1.1 Cluster Analysis 
The purpose of clustering techniques is to detect similar subgroups among a large 
collection of cases and to assign the homogeneous observations into one cluster. The 
clusters are assigned a sequential sequence number to identify them in results reports. In 
most cases, it is performed to reduce sample size and to prepare for another analysis. The 
primary algorithms of clustering are k-means clustering, EM (Expectation Maximization) 
clustering and hierarchical clustering. 
1. K -means Clustering 
The k -means algorithm [24] is an old and simple method applied in cluster 
analysis. The process can be operated in this way: first, a fixed number of clusters, k is 
given; then, observations are assigned to those clusters so that the means across clusters 
are as terms different from each other as possible. The difference between observations is 
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measured in a distance measure such as Euclidean or Squared Euclidean. 
2. EM Clustering 
Expectation Maximization [51] is another algorithm for clustering and its goal is 
to find the most likely set of clusters for the observations. The basis of this approach is a 
body of statistical theory, called finite mixture, in which a set of probability distributions 
represent k clusters. The technique consists of two steps, E-step (estimation) and M-step 
(maximization). 
E-step: to compute the conditional expectation: 
Q(O;OU)) = Eo," (log L(O, y)1 Yo) 
(4.1 ) 
M-step: to find thee, which maximizes the expectation: 
A (1+1) A (TI 
o = arg max Q( 01 0 
e (4.2) 
These two steps are repeated until 
(4.3) 
where L (0, y) is a likelihood function, Q: e, (1)) is a conditional expectation, e is an 
unknown parameter and fJ U ) is the estimate of the unknown parameter at iteration t >0, 
and £ is a very small positive number. 
3. Hierarchical Clustering 
Hierarchical clustering [52] is another algorithm for clustering, in which Ward's 
method is utilized. We first defined several terminologies, error sum of squares, 
total sum of squares, T and R2 and they are shown in Equations (4.4) - (4.6). 
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Error Sum of Squares: (4.4) 
Total Sum of Squares: (4.5) 
2 T-8 R=-
r (4.6) 
In the above equations, X ijk denotes the value for the variable k in observation j belonging 
to cluster i; X
ik 
stands for the cluster mean for that variable; x, denotes the grand mean 
for that variable. Using Ward's method, the like units should be clustered together in each 
step; therefore, the error should be computed and minimized (or if the selection criterion 
is R2 instead, then it should be maximized) in each step. At the end of the process, a 
single large cluster of size n will be formed. The process starts with all sample units in n 
clusters of size 1. Then, the clusters or observations are combined in such a way to 
minimize the error or maximize R2. In that way, n-l clusters are formed in the first step, 
n-2 clusters are generated in the second step, and this process will not stop until all 
sample units are combined into one cluster. 
4. Comments 
We apply the last two methods of clustering. The merit of clustering analysis is 
that it is simple and easy to perform. It provides a quick way to explore the data structure 
without providing an explanation or interpretation, especially if the objects are classified 
into many groups. However, it cannot be used to predict either the relationships between 
different groups or the relationships between the predictors and the predicted variables. 
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4.1.2 Association Rule Analysis 
Association rule analysis [53], often referred to as market basket analysis, is used 
to investigate relationships or associations between specific values of categorical 
variables in large data sets. This technique can be used to uncover hidden patterns in 
large data sets, and hence, it is especially well suited for data mining. 
1. Basic Rule 
The goal of association rule analysis is to find subsets of variable values Sf, S2 .. S/I· 
such that the probability of each of the variables simultaneously assumes that a value 
within their respective subsets, 
(4.7) 
is relatively large. If we apply dummy variables, and Xi stands for a variable, xij is the /" 
observation of the variable Xi , i means a set of all items associated with the variable Xi, 
S( J) is the support of f, and t is the lower support bound; then the formulation of the rule 
IS: 
iEI iE! (4.8) 
and the purpose is to find all the item sets fm that meet the following condition: 
(4.9) 
2. Confidence, Support and Lift 
According to the rules, a high support item returned can be partitioned into 
two subsets, A and B such that 
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AuB=! 
{ 
AnB=¢ 
(4.10) 
If A is the antecedent, and B is the consequence, then the confidence can be defined in 
this way: given that event A occurs, the probability that B also happens is equal to 
P(BI A) = #of(A => B) 
#A 
(4.11) 
The support is defined as the ratio of the number of both events, A and B, appearing 
together compared to the number of total transactions: 
peA n B) = #of(A n B) 
# of all 
The lift can be written as the ratio of confidence and its expected confidence: 
peL) _ _ P_( B--,---iA_) 
- E(Bi A ) 
(4.12) 
(4.13) 
When studying the associations between items, the confidence, the support and the lift 
should be considered. The basic rule is that the higher the value of these three measures, 
the stronger the relations. 
3. Application 
Association rule analysis is one of the popular marketing strategies; many 
retailers utilize it to find potential customers and increase their response rate when they 
mail their product catalogs to their targeted customers. In our research, we apply it to 
medical procedures. For instance, we explore whether the patients receive procedures 
related to heart disease along with what additional procedures and treatments are also 
given to them. 
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4.2 Supervised Machine Learning 
Although unsupervised learning has some merits, it cannot be utilized for accurate 
prediction. Therefore, supervised learning algorithms are frequently used. In our research, 
we often employ the decision tree model, the neural network model, and the rule 
induction model. We then compare these models to find the optimal one. In this section, 
we will discuss these models. 
4.2.1 Decision Tree Model 
We can apply three algorithms to the decision tree model in SAS EM (Enterprise 
Miner 6.2): (1) the default tree methodology in EM, (2) CHAID (Chi-square automatic 
interaction detection), and (3) CART (Classification and regression tree). 
1. The Default Algorithm 
We first discuss the default methodology [52] for the decision tree model in SAS 
EM; it is a little different from the other two algorithms. The main idea of this approach 
can be explained in this way: 
• The split is based on some measures, either a node impurity measure or / test; 
the F test criteria, i.e. the p- value can also be utilized. 
• If the node has many observations, then a sample is used for the split search. 
• If the target is binary, nominal or ordinal, then the sample should be as balanced 
as possible. 
• If after consolidation, the number of possible splits is greater than the number 
specified, then a heuristic search is used. 
• At the beginning of the heuristic algorithm, each consolidated group of 
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observations is assigned to a different branch; then at each step, the two branches 
are merged; the process will not stop until no group can be assigned. 
2. CHAID Algorithm 
The algorithm, CHAID [541. applied in decision tree model building, was 
originally proposed by Kass in 1980. Although this method can be utilized for both a 
continuous dependent variable and a categorical target, here, we discuss the latter .The 
method consists of three steps: merging, splitting and stopping. 
Merging step: In this step, a significant value Umerge should be defined at the beginning; 
then, by the equations shown in (4.14) - (4.16), the variable X.2 and the p -value can be 
computed. If the significance (i.e., p-value) for a given pair of categories is larger than 
Umerge, then it will merge the respective predictor categories; otherwise, the adjusted p-
value will be computed using the equation displayed in (4.17). 
J I ( _(jJ)2 
X2 = II 'It) Ij 
j '=l i=l (fJ. Ij 
(4.14) 
where IJIj is the observed cell frequency, liJlj is the estimated expected cell frequency 
for cell (xn= i, Yn= j) and there are i categories of predictor X and j categories of the 
dependent variable Y. 
(4.15) 
(4.16) 
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where Xd follows a l distribution with degrees of freedom d = (1- 1 )(1- 1). The adjusted 
p-value is calculated as the p-value multiplied by fJ (defined in Equation (4.18)). Suppose 
that the total number categories of X is I, and after several merges, r classes are left. If 
2:'S: r < I, then 
Padjustea P * f3 (4.17) 
/3= f(-l)k (r-k)! 
k=JJ k!(r-k)! ( 4.18) 
Splitting step: In this step, the adjusted p-value of each predictor will be compared with 
the user-defined a,plit. If the adjusted p-value is not greater than the a'pIit, then its 
corresponding predictor is used for the split; otherwise, the node is the terminal one. 
Stopping step: The splitting step will continue until no more splits can be performed. 
During development, a tree with a binary target is generated by repeatedly using the 
above three steps on each node starting from the root node using the CHAID algorithm. 
3. CART Algorithm 
The Classification and regression tree methodology [24] was first introduced in 
1984 by UC Berkeley and Stanford researchers Leo Breiman et al. This algorithm can be 
implemented in two cases: the classification tree is used for a categorical predicted 
variable while the regression tree is used for a continuous predicted variable. The primary 
techniques included in this algorithm are how to select splits and how to prune a tree [49]. 
(1) Selecting Splits: The rule of thumb is that the split at each node will improve the 
predictive accuracy to the greatest extent. For classification trees, there are several 
impurity measures, including l, G2 or the Gini index (shown in (4.19)), among which the 
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Gini index is the most frequently used criterion, 
11 
Gini(S) = I Pi Pi = 1- I pJ 
)=1 (4.19) 
where S is a set containing n classes, and Pi is the relative frequency of class j in S. For 
regression trees, a least squares deviation is most frequently used. If N w (S) represents the 
weighted number of cases in node S, Wi is the value of the weighting variable for case 
i, Ii is the value of the frequency variable, Yi represents the value of the dependent 
variable, and yeS) is the weighted mean for node S, then a least squares deviation can be 
computed as: 
(4.20) 
(2) Pruning Trees: For the CART algorithm, it is more important to prune back to find 
the optimal tree than to find when to stop splitting. A tool called V-fold cross validation 
can be used to prune a tree, and the process can be addressed in the following way: 
• Partition the entire data set into V folders. 
• Train V folders on different combinations of V-I folds and estimate the error for 
the fold that is left out of the tree at each time. 
• Estimate tree accuracy based on the error measurements. 
• Find the design parameters to minimize the error. 
• Refit the tree using all of the data, the chosen parameters. 
4. Comments 
The CHAID algorithm can build non-binary trees, which makes it popular among 
market researchers while the CART algorithm is always building binary trees. One of the 
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characteristics of the decision tree model in SAS is that it can demonstrate the importance 
of the variables. A rule of thumb is that the level where a variable lies indicates its 
importance. The higher the level, the more vital the variable. In addition, compared to 
other methodologies, the decision tree model has three primary advantages. First, it is 
non-parametric and non linear and hence it does not require specifications of a data 
distribution. Moreover, it can automatically group the missing values into one category 
without preprocessing them. In addition, its output is easy to understand and interpret. 
Therefore, the decision tree model is a very popular tool for decision makers. 
4.2.2 Neural Network Model 
The neural network model [55], often simply called Neural Nets, originated from 
early understandings of the structure and function of the human brain. The type of the 
model that we utilize is MLP (Multilayer perceptron), and the algorithm is back 
propagation. In this section, we will focus on this algorithm and this type of neural 
network. 
1. Basic Rule 
Input 
la),cr 
llid-ticn 
lay"" 
()Ulput 
layer 
Figure 4.1. A Feed-forward Neural Networks 
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As figure 4.1 [55] demonstrates, the structure of an MLP consists of neurons 
organized in three layers: input layer, hidden layer and output layer. Weights Wu are 
assigned to each connection between the input neuron and the middle neuron, and 
between the middle neuron and the output neurons. With nonlinear transfer functions, 
hidden neurons can process complex information received from input neurons and then 
send processed information to output layer for further processing to generate outputs. The 
whole process of MLP can be described in the following way: 
Step 1: The inputs Xi are combined together to form a weighted sum of inputs and the 
weights Wi of connecting links. 
Step 2: A transformation is performed to convert the sum to an output via a transfer 
function/, and a transformation can be expressed in Equation (4.21). Among all transfer 
functions, the logistic function is the most popular one. 
(4.21) 
Step 3: Network output values are calculated and compared to the target values and the 
weights of the connections are changed to produce a better approximation to the desired 
output. The way of adjusting the weights is demonstrated in Equations (4.22). 
nell' old old dE 
Wij = Wij + .L\wij = Wi; + (-77a-) 
ij (4.22) 
in which E is the objective function and 77 is the learning rate which controls the size of 
the gradient descent step. 
Step 4: The above step will repeat until the output is ideal. 
2. Comments 
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Besides MLP, there are several other types of neural networks such as auto neural 
networks, linear networks, Bayesian networks, etc. A neural network can be thought of as 
a complicated combination of regression models, but it is a powerful classifier. It can 
handle problems with many parameters, and it tends to fit the training data well and thus 
has low bias. Therefore, in most cases, this model outperforms other models. If it is the 
optimal model, we should use another tool to express the information in an easily-
understood way. 
4.2.3 The Other Models 
1. Rule Induction 
Rule induction [29] is another tree-based algorithm for classification. It is mainly 
utilized to improve the classification ofrare events. Usually rules are expressions of the 
form: 
({(attribllte-I, vallie-I) and (attribllte-2, vallle-2) and· .. and (aftribllte-n, value-n) 
then (decision, value). 
Some rule induction systems induce more complex rules, in which values of attributes 
may be expressed by the negation of some values or by a value subset of the attribute 
domain. 
2. Memory-Based Reasoning 
MBR (Memory- Based Reasoning) [52] tries to mimic human behavior in an 
automatic way. MBR needs a distance measure to assign the dissimilarity of two 
observations and a combination function to combine the results from the neighboring 
points to achieve an answer. The distance measure is the k-nearest neighbor algorithm, in 
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which the k- nearest neighbors are determined by the Euclidean distance between an 
observation and the probe. By MBR means, it is easier to generate examples than to 
generate rules, and hence this method is very attracti ve. 
4.3 Data Mining Model Comparison 
After developing various models, several measures [56] can be used to find the 
optimal model, including the AIC (Akaike Information Criterion), the BIC criterion 
(Bayesian Information Criterion), the ROC (Receiver Operating Characteristic) curve, the 
Lift Chart and the misclassification rate, etc. We have already discussed the first two 
criteria in Chapter III, and hence we will introduce the other measures in this section. 
4.3.1 ROC Curve 
The ROC curve is a graph (shown in Figure 4.2, part of Figure 6.7) that measures 
the predictive accuracy of a model. In a Cartesian plane, the x-axis represents the false 
positive value (a.k.a. I-specificity) and the y-axis represents the sensitivity value. Each 
point in the curve corresponds to a particular cut-off. The model where the ROC curve is 
leftmost is the best model among the different models. 
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Figure 4.2. The ROC Curve 
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4.3.2 Lift Chart 
A lift chart (displayed in figure 4.3[56] ) is another graph criterion of measuring 
the predictive accuracy of models. The scored data set is sorted by the probabilities of the 
target event in descending order; observations are then grouped into deciles. For each 
decile, a lift chart can calculate the ratio between the result obtained with a model and the 
result obtained without a model that is based on randomly selected records. In the chart, it 
is represented by the horizontal base line. Lift charts show the percentage of positive 
response or the lift value on the vertical axis. If the distance between a curve and the 
base line is the greatest, then the model to which the curve corresponds is the best one. 
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Figure 4.3. The Lift Chart 
4.3.3 Misclassification Rate 
When comparing the models, we often utilized the misclassification rate. We 
divide the sample into decision regions Rill, for each class Ck • Misc1assification 
occurs if the input vector x belonging to C; is assigned to Cj , where i '* j , the 
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misclassification rate can be computed as: 
p", = I Jp(x,C)dx 
R· 
1 " 
(4.23) 
The optimal model should be the one whose misclassification rate is the minimum. 
Up to this point, we have discussed the basic data processing methodologies, 
basic concepts and the primary theories or algorithms that we will often use in our 
research. As we move into the chapters ahead, we will become immersed in studying 
diabetes outpatients and inpatients in the Medicare population without further discussing 
these theories and algorithms. 
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CHAPTER V 
COST ANALYSIS OF MEDICARE OUTPATIENTS 
WITH DIABETES 
Outpatients with diabetes use considerable Medicare resources, and hence it is 
essential to take measures to reduce the costs. The primary purpose of this chapter is to 
address this problem from prevention and medical services perspectives. We will first 
introduce some knowledge about descriptive statistics and correlation analysis; then we 
propose methods to decrease Medicare payments through analyses of claims data and 
data from revenue centers for outpatients. 
5.1 Descriptive Statistics 
Descriptive statistics [57] are used to quantitatively describe the basic features of 
the data in a study and they include four types: (l) measures of central tendency 
including the arithmetic mean, median and mode, etc.; (2) measures of dispersion such as 
the standard deviance; (3) measures of association such as odds ratio and correlations 
coefficients; (4) a non-parametric analysis such as kernel density estimation. In this 
section, we will talk about the last two types. 
5.1.1 Kernel Density Estimation 
In statistics, kernel density estimation [57] is a non-parametric way of estimating 
the probability density function of a random variable. For our research, we use the 
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univariate case. The kernel estimator for the univariate case can be defined as: 
1\ 1 II x-X. 
f(x;h)=-LK( ') 
nh ;=1 h (5.1) 
where XI, X 2, ... Xn are independent and identically distributed random variables; f is 
the density function; K stands for some known density function and h is a smoothing 
parameter called the bandwidth. As an illustration, given some data about a sample of a 
population, kernel density estimation makes it possible to extrapolate the data to the 
entire population. To better display the distribution, it is important to make sure that the 
smoothness of the graph is reasonable, which is decided by the bandwidth. One simple 
method to choose the optimal bandwidth is to find the minimum of the asymptotic mean 
integrated squared error (AMISE, defined below) with respect to h, 
R(K) 1 -4 4 " 
AMISE= --+-(jkh R(f (x)) 
nh 4 
where R(K)= jK
2
(x)dx. 
5.1.2 Pearson Correlation Analysis 
(5.2) 
Correlation analysis is a common method of studying the relations between two or 
more variables. The typical measure for the linear relationship analysis is the Pearson 
correlation coefficient. The Pearson Product-Moment Correlation coefficient r [58], 
simply called the Pearson coefficient gives information about the degree and the 
directions of how the two variables are related. Its computation is based on covariance 
and its value range is [-1,1]. The values ±l mean that there exists a perfect positive or 
negative linear relationship between the two variables; the intervals of [-1, - 0.75) or 
[0.75, 1) indicate a high degree of correlation; the intervals of [-.25,0) or (0, 0.25] 
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indicate a low degree of correlation; the value 0 means that there is no predictability. 
When it comes to the sample analysis, the sample coefficient R is seldom utilized; instead, 
R2 is frequently utilized to display the relationship between the dependent variable and 
the predictors. The formula for rand R are shown below. 
(5.3) 
~)(Xi - ~)(Yi - y)) 
R= i 
J'L)Xi - X)2 ~:CYi - y)2 
I I 
(5.4) 
In the above two formulas, cov (x,y) denotes the covariance; f.1" f.1" (j', 2 ,(j', 2 respectively 
represent the expectations and the variances of the variables x. y; x, y denote the sample 
mean of x and y. 
5.2 Cost Analysis using Data from Revenue Center 
In this section, we use data from the revenue center and demographic data for 
diabetes outpatients in Medicare from the CMS CCW data [181 to find ways to decrease 
the costs through the general linear model and the generalized linear model as well as 
Pearson correlation analysis. 
5.2.1 Kernel Density Estimation 
After using Filter and Query in SAS EG (Enterprise Guide) 4.1 to select the 
necessary variables and combine two data sets together, we perform KDE (kernel density 
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estimation) to see the differences in the costs among different races. The SAS code and 
the results are shown below: 
PROC SORT DATA=SASUSER.RANSAMPLE 
BY BENE_RACE_CD BENE_SEX_IDENT_CD ; 
PROC KDE DATA=SASUSER. SRANSAM ; 
OUT=SASUSER. SRANSAM ; 
UNIVAR REV_ CNTR_ TOT_ CHRG_AMT/ GRIDL=O GRIDU=1500 
METHOD=SNR OUT=SASUSER.KDECHAR ; RUN ; 
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FigureS.I. KDE of Costs among Different Races (Male) 
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Figure 5.2. KDE of Costs among Different Races (Female) 
Figures 5.1 & 5.2 visualize the distributions of the costs; the densities of costs for 
males and females follow gamma distributions and all of them approach zero after 1500 
dollars. The costs of the whites have a higher probability of being lower compared to all 
other races. There exist differences between the males and the females; the densities 
arrive at the peak when the costs reach 50 dollars for males and 100 dollars for the 
females. 
5.2.2 Statistical Model Analysis 
We want to find the reasons for Medicare payments from diagnosis information 
utilizing the linear statistical models. Prior to analysis, we used the One-Way Frequency 
in SAS EG to find the top 20 procedures displayed in Table 5.1 [23]. 
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Table 5.1 Top 20 HCPCS Codes 
82962 Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home 
use 
2 GOOOI Routine venipuncture for collection of specimen(s) 
3 97110 Therapeutic procedure, therapeutic exercises to develop strength and endurance, range of 
motion and flexibility 
4 85025 Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and 
automated differential WBC count 
5 85610 Prothrombin time; 
6 80048 Basic metabolic panel 
7 80053 Comprehensive metabolic panel 
8 83036 Hemoglobin; glycosylated (A I C) 
9 90999 Unlisted dialysis procedure, inpatient or outpatient 
10 97530 Therapeutic activities, direct (one-on-one) patient contact by the provider (use of dynamic 
activities to improve functional performance), 
11 Q4055 Injection, 
12 80061 Lipid panel 
13 97116 Therapeutic procedures ;gait training (includes stair climbing) 
14 97112 Therapeutic procedure,; neuromuscular reeducation of movement, balance, coordination, 
kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities 
15 99212 Office or other outpatient visit for the evaluation and management of an established patient; 
Physicians typically spend 10 minutes face-to-face with the patient and/or family. 
16 93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation 
and report 
17 99213 Office or other outpatient visit for the evaluation and management of an established patient 
physicians typically spend 15 minutes face-to-face with the patient and/or family. 
18 A4657 Syringe, with or without needle, each 
19 84443 Thyroid stimulating hormone (TSH) 
20 71020 Radiologic examination, chest, two views, frontal and lateral; 
Some of extracted 20 HCPCS codes are regular diabetes examination procedure 
such as A1C test (HCPCS: 83036) and some of them are procedures needed by diabetes 
complications such as an Electrocardiogram (HCPCS: 93005). The 20 codes are 
recorded as binary 0-1 indicator functions in 20 columns with SAS coding. We can use 
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Analyze->ANOV A->Linear Model with costs as the dependent variables; the newly-
generated 20 indicator variables were used as the class variables in the model. The results 
are given below: 
Table 5.2 Overall the General Linear Model Information 
R-Square CoefTVar RootMSE REV _CNTR_TOT_CHRG_AMT Mean 
0.033549 434.3811 1737.414 399.9746 
The r-square value is 3.3%, which means that 3% of the variability of the costs 
can be explained by the above 20 factors. Although this is a small number, it gives us an 
idea of what is significant. Table 5.3 shows that the 20 variables are significant to the 
costs. However, since the distributions of the costs are gamma distributions, we should 
also consider the generalized linear model with a gamma distribution. 
Table 5.3 Type III Sum of Squares 
Source DF Type III SS Mean Square F Value Pr>F 
Blood glucose monitoring I 144951012755 144951012755 48019.2 <.0001 
Routine venipuncture I 135540500264 135540500264 44901.7 <.0001 
Therapeutic exercises to develop strength and endurance I 76340503128 76340503128 25290.0 <.0001 
Blood count I 60850533348 60850533348 20158.5 <.0001 
Prothrombin time I 57263486670 57263486670 18970.2 <.0001 
Basic metabolic panel I 37054519078 37054519078 12275.4 <.0001 
tc=omprehensive metabolic panel I 30419948211 30419948211 10077.5 <.0001 
Hemoglobin; glycosylated I 37500526373 37500526373 12423.1 <.0001 
Unlisted dialysis procedure, I 417296629150 417296629150 138241 <.0001 
Therapeutic activities, direct patient contact by the I 34114806835 34114806835 11301.5 <.0001 
Injection I 169829929901 169829929901 56261.0 <.0001 
Lipid panel I 26676907909 26676907909 8837.49 <.0001 
Therapeutic procedure, gait training I 29359815777 29359815777 9726.28 <.0001 
Neuromuscular reeducation of movement, balance I 24582913341 24582913341 8143.79 <.0001 
office or other outpatient visit, typically 10 minutes I 20034618172 20034618172 6637.04 <.0001 
Electrocardiogram, (EGG) I 13816375074 13816375074 4577.07 <.0001 
Office or other outpatient visit, typically 15minutes I 17996085232 17996085232 5961.72 <.0001 
Syringe, I 20096703187 20096703187 6657.61 <.0001 
Thyroid stimulating hormone I 15385539003 15385539003 5096.90 <.0001 
Radiologic examination I 8767439243.1 8767439243.1 2904.47 <.0001 
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Table5.4 Criteria for Assessing Goodness of Fit 
Criteria For Assessing Goodness Of Fit 
Criterion DF Value ValuelDF 
Deviance 9964 22374.1763 2.2455 
Scaled Deviance 9964 12474.8191 1.2520 
Pearson Chi-Square 9964 I 130667.2143 13.1139 
Scaled Pearson X2 9964 72854.0725 7.3117 
... --
Log Likelihood -63303.4243 
In Table 5.4, the value of deviance divided by degree is 2.25.The value shows the 
adequacy of this model, which means that the model fits the data reasonably well. In 
Table 5.5, all the p values are smaller than 0.0001, indicating that all 20 variables are 
statistically significant. The l value of 1070.13 for blood glucose monitoring represents 
twice the difference in log likelihoods between fitting a model with only an intercept and 
a model with an intercept and blood glucose monitoring. Similarly, every l value for 
each variable represents the differences in log likelihoods between successive models. 
The output shows that the X2 values for venipuncture and blood glucose monitoring are 
the highest among all the X2 values; therefore, we conclude that blood glucose monitoring 
and venipuncture have more important effects on the costs than any other treatments do. 
Table 5.5 Type I analysis 
LR Statistics For Type 1 Analysis 
Source 2 *LogLikelihood DF Chi-Square Pr> ChiSq 
Intercept -131538.88 
Blood glucose monitoring -130468.75 I 1070.13 <.0001 
Routine venipuncture -129441.88 I 1026.87 <.0001 
Therapeutic exercises -129197.95 I 243.93 <.0001 
Blood count -128915.08 I 282.87 <.0001 
Prothrombin time -128568.73 I 346.35 <.0001 
.•. .'---- --- -------:--
Basic metabolic panel -128424.85 I 143.88 <.0001 
Comprehensive metabolic panel -128315.64 I 109.21 <.0001 
Hemoglobin; glycosylated -128081.87 I 233.78 <.0001 
Unlisted dialysis procedure -127823.38 I 258.49 <.0001 
Therapeutic activities, direct patients contact by the -127633.20 I 190.18 <.0001 
Injection -127565.57 I 67.63 <.0001 
Lipid panel -127459.23 I 106.34 <.0001 
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LR Statistics For Type I Analysis 
Source 2*LogLikelihood DF Chi-Square Pr > ChiSq 
Therapeutic procedure, gait training -127263.69 I 195.55 <.0001 
Neuromuscular reeducation of movement, balance -127112.20 I 151.48 <.0001 
Office or other outpatient visit, typically 10 minutes -127004.16 I 108.04 <.0001 
Electrocardiogram, EGG -126952.54 I 51.62 <.0001 
Office or other outpatient visit, typically 15 minutes -126855.49 I 97.05 <.0001 
Syringe -126711.41 I 144.09 <.0001 
Thyroid stimulating hormone -126640.03 I 
-- -- --- ._- -.. ~---~ c---
<.0001 71.37 
Radiologic examination -126606.85 I 33.18 <.0001 
Table 5.6 Pearson Correlation 
Pearson Correlation Coefficients, N = 12158258 
coefficients 
Blood glucose monitoring -0.05110 «.0001) 
Routinevenipunctureforco llectionspeci men( s) -0.04919 «.0001 ) 
In Table 5.6, the negative correlation coefficients between the total charges and 
blood glucose monitoring and routine venipuncture indicate that if we increase the 
monitoring and routine venipuncture, we can decrease the total charges. 
5.3 Cost Analysis Using Claims Data 
5.3.1 Newly-generated Predictors 
In this section, we will analyze the relationships between the diagnosis and the 
costs of outpatients with diabetes using the Medicare claims data from the CMS CCW 
data warehouse [18]. In these data, diagnosed diseases or procedures appear in more than 
2 columns; therefore, we use the method in [59] to get them into one column. First, we 
use Filter and Query to select Claim ID and ICD9_DGNS_CDI to generate a new data 
set that contains two columns, and change the name ofICD9_DGNS_CDI to ICD9. It is 
the same for the left nine ICD9_DGNS_CDn and six ICD9_PRCDR_CD n to generate 16 
Tables. Then, we open one Table, and use Data - >Append Table; after that, the ICD9 
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Table (Figure 5.3) is generated. This is followed by Describe->One-way 
Frequencies to find the top 20 ICD9 codes as displayed in Table 5.7. 
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Figure 5.3. ICD9 Table 
Table 5.7 Top 20 ICD9 Diagnosis Codes 
ICD9 Diagnosis Frequency Percent 
25000 Diabetes mellitus without complication type ii or unspecified type not 2264 8.90 
stated uncontrolled 
4019 Unspecified essenti al hypertension 135 1 5.31 
585 Chronic kidney di sease (ckd) 629 2.47 
V5861 Long-term (current) use of anticoagulants 509 2.00 
2724 Other and unspecified hyperlipidemia 508 2.00 
--- --
42731 Atrial fibrillati on 469 1.84 
2859 Anemia unspecified 452 1.78 
4280 Congesti ve heart failure unspecified 429 1.69 
V5869 Long-term (current) use of other medicat ions 402 1.58 
28521 Anemia in chroni c kidney disease 357 1.40 
4011 Benign essential hypertension 339 1.33 
2720 Pure hypercholesterolemia 3 14 1.23 
41400 Coronary atherosclerosis of unspecified type of vessel nati ve or graft 296 1.1 6 
25001 Diabetes mellitus without complication type i not stated as uncontrolled 244 0.96 
5990 Urinary tract infection site not specified 232 0.9 1 
2809 Iron defi ciency anemi a unspecified 230 0.90 
2449 Unspecified acquired hypothyroidism 225 0.88 
496 Chronic airway obstruction not elsewhere classified 2 10 0.83 
25002 Diabetes mellitus without complication type ii or unspecified type 203 0.80 
78079 Other malaise and fati gue 194 0.76 
Next, we process the data to get the data (Figure 5.4) ready for analysis. 
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Figure 5.4. Newly-generated Data for GLM 
5.3.2 Statistical Model Analysis 
After the assumptions diagnostics, the generalized linear model is developed, with 
the costs as the predicted variable and the newly-generated variables as the input 
variables. The results are given in the following Tables. 
Table 5.8 Overall Mode Information 
Model Information 
Data Set WORK.SORTIEMPTAB 
LESORTED 
Distribution Gamma 
Link Function Log 
Dependent Variable CLM_TOT_CHRG_AMT Claim Total Charge 
Amount 
Table 5.8 gives information about distribution of the response variable, the link 
function. In Table 5.9, the value of deviance divided by degree is 2.32, and the scaled 
deviance divided by degree is 1.26. These two parameters demonstrate the adequacy of 
this model, which means that the generalized linear model fits the data reasonably well. 
Table 5.9 Criteria for Assessing Goodness Fit 
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Criteria For Assessing Goodness Of Fit 
Criterion DF Value ValuelDF 
Deviance 9980 23196.7333 2.3243 
Scaled Deviance 9980 12550.5608 1.2576 
Pearson Chi-Square 9980 79786.4792 7.9946 
Scaled Pearson X2 9980 43168.3655 4.3255 
Log Likelihood -75829.4983 
Table 5.10 Type lAnai ysis 
LR Statistics For Type 1 Analysis 
Source 2*LogLike- DF Chi- Pr 
Square 
Intercept -154184.45 
R25000_Max Diabetes mellitus without complication type II or -154160.76 I 23.68 <.0001 
unspecified type uncontrolled 
R4019_Max Unspecified essential hypertension -154078.23 I 82.53 <.0001 
R585_Max Chronic kidney disease (ckd) -152265.81 I 1812.42 <.0001 
RV586 I_Max Long-term (current) use of anticoagulants -152018.52 I 247.29 <.0001 
R2724_Max Other and unspecified hyperlipidemia -151969.30 I 49.21 <.0001 
R4280_Max Congestive heart failure unspecified -151953.57 I 15.74 <.0001 
R4273 I_Max Atrial fibrillation -151889.81 I 63.76 <.0001 
RV5869_Max Long-term (current) use of other medications -151886.98 I 2.82 0.0929 
--_._.- ._----
R2859_Max Anemia unspecified -151880.30 I 6.69 0.0097 
---- ---- ._-----f--_ .. 
R4011_Max Benign essential hypertension -151782.39 I 97.91 <.0001 
R28521_Max Anemia in chronic kidney disease -151737.71 I 44.68 <.0001 
R2720_Max Pure hypercholesterolemia -151736.64 I 1.07 0.3014 
R41400_Max Coronary atherosclerosis of unspecified type of -151731.99 I 4.65 0.0311 
vessel native or graft 
R5990_Max Urinary tract infection site not specified -151731.98 I 0.01 0.9287 
R25001_Max Diabetes mellitus without complication type i not -151729.57 I 2.41 0.1203 
stated as uncontrolled 
R78079_Max Other malaise and fatigue -151729.57 0 0.00 
R2809_Max Iron deficiency anemia unspecified -151708.85 I 20.72 <.0001 
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LR Statistics For Type I Analysis 
Source 2*LogLike- DF 
R2449_Max Unspecified acquired hypothyroidism -151707.74 I 
R496_Max Chronic airway obstruction not elsewhere -151698.50 I 
classified 
R25002_Max Diabetes mellitus without complication type ii or -151659.00 I 
unspecified type uncontrolled 
Table 5.11 Variables Significant to the Model 
Diabetes mellitus without complication type II or unspecified 
type uncontrolled 
R585_Max 
RV5861_Max 
R42731_Max 
R2859_Max 
R4011_Max 
R28521_Max 
Unspecified essential hypertension 
Chronic kidney disease (ckd) 
Long-term (current) use of anticoagulants 
Other and unspecified hyperlipidemia 
Congestive heart failure unspecified 
Atrial fibrillation 
Anemia unspecified 
Benign essential hypertension 
Anemia in chronic kidney disease 
Chi-
Square 
1.11 
9.24 
39.50 
Coronary atherosclerosis of unspecified type of vessel native or 
graft 
R78079_Max 
R2809_Max 
Other malaise and fatigue 
Iron deficiency anemia unspecified 
Chronic airway obstruction not elsewhere classified 
Diabetes mellitus without complication type ii or unspecified 
type uncontrolled 
Type I analysis shows that the following factors (shown in Table 5.11) are 
Pr 
0.2922 
0.0024 
<.0001 
statistically significant to the model. Since the l value for chronic kidney disease ranks 
the first among all the values (shown in Table 5.1 0), kidney disease is the most important 
variable related to the costs. 
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Since chronic kidney disease has the most important effect on the costs and 
chronic kidney disease counts for a large percentage of renal failure, the logistic 
regression in Enterprise Miner will be used to analyze the relationships between renal 
failure and the other diseases vital to the costs. Before that, a binary variable, Renal is 
generated using 0-1 indicator functions. The following steps are conducted in Enterprise 
Miner. First, R (Renal Failure) is set as the target and the variables are set on binary level. 
Then, a sample node is added and connected to the data; and the Stratify Method is used, 
choosing Level Based as the stratified criterion and Rarest Level in the Level Based 
options. The results are as shown in Tables 5.12 - 5.15. 
Table 5.12 Misclassification Rate 
TARGET Fit Statistic Label Train Validation Test 
R_Max Misclassification Rate 0.38596491 NaN NaN 
Table 5.13 Type 3 Analysis of Effects 
Effect D Wald Pr> 
F ChiSq ChiSq 
Unspecified acquired hypothyroidism I 0.028 0.866 
Diabetes mellitus without complication type ii or I 1.131 0.288 
unspecified type not stated as uncontrolled 
Diabetes mellitus without complication type i not I 0.360 0.548 
stated as uncontrolled 
Diabetes mellitus without complication type ii or I 0.027 0.868 
unspecified tvpe uncontrolled 
Anemia unspecified I 4.708 0.030 
Benign essential hypertension I 0.264 0.607 
Coronary atherosclerosis of unspecified type of vessel I 0.012 0.910 
native or graft 
Atrial fibrillation I 0.151 0.697 
Congestive heart failure unspecified I 0.226 0.634 
Chronic airway obstruction not elsewhere classified I 0.562 0.453 
Chronic kidney disease (ckd) I 0.428 0.513 
Urinary tract infection site not specified I 2.596 0.107 
Long-term (current) use of anticoagulants I O.fXl 0.929 
Long-term (current) use of other medications I 0.015 0.902 
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------- -------------
The misclassification rate in Table 5.12 is 0.386, which is accepted. The results in 
Table 5.13 indicate that only unspecified anemia is significant to renal failure as only its 
p-value in the Type 3 analysis is less than 0.05 out of the 15 diseases that are considered 
for renal failure. The odds ratio for Anemia in Table 5.14 shows that if the diagnosis is 
not anemia, then the chance that it is related to renal failure is only 9 % of the probability 
that it is Anemia. Hence, Anemia has the most prominent relationship to renal failure. 
Table 5.14 Odds Ratio Estimates 
Effect Diagnosis Point 
Estimat 
R2449 _Max 0 vs I Unspecified acquired hypothyroidism 0.745 
R25000_Max 0 vsl Diabetes mellitus without 2.057 
complication type ii or unspecified 
R25001 Max 0 vsl Diabetes mellitus without 0.602 -
complication type i not stated as 
R25002_Max 0 vs I Diabetes mellitus without 0.840 
complication type ii or unspecified 
R2859 _Max 0 vs I Anemia unspecified 0.093 
R4011 - Max 0 vs I Benign essential hypertension 0.562 
R41400_Max 0 vs I Coronary atherosclerosis of 1.145 
unspecified type of vessel native or 
R4273 1 Max 0 vsl Atrial fibrillation 1.551 -
R4280_Max 0 vs I Congestive heart failure unspecified 0.704 
R496_Max o vs I Chronic airway obstruction not 0.402 
elsewhere classified 
R585_Max ° vs I Chronic kidney disease (ckd) 0.626 
R5990_Max 0 vs I Urinary tract infection site not 0.121 
specified 
RV5861 - Max 0 vsl Long-term (current) use of 1.139 
anticoagulants 
RV5869_Max 0 vsl Long-term (current) use of other 0.794 
medications 
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Table 5.15 Event Classification Table 
Data Role Target False Negative True False Positive True Positive 
Ne.l(ative 
Train R_Max 32 45 12 25 
Table 5.15 shows that the false negative rate is 32 %, which means that it is 32% 
likely for the model to predict that renal failure is not occurring when it in fact is; the 
false positive rate is 12, which means that it is only 12 % likely to predict the diagnosis of 
renal failure when it actually does not occur. Since a false negative is more critical than a 
false positive, the model is fairly good. 
Just as the results show, the model probably needs improving; hence, it is 
necessary to utilize another model to analyze the relationship. Next, we utilized the 
generalized linear mixed model, in which the GLIMMIX procedure in SAS can be used, 
selecting Renal as the response variable, which is a binary variable; selecting Ane 
(Anemia), Hea (Heart disease) and Unctrl (Uncontrolled diabetes) as the classification 
variables; analyzing Ane and Hea in the fixed effects while analyzing Unctrl in the 
random effects. The least-squares means for Ane and Hea are also used. The following 
SAS code is used. 
PROC GLIMIX DATA=SASUSER.RENAL; 
CLASS HEA ANE UNCTRL; 
MODEL RENAL=ANE HEA/DIST=BINARY LINK=LOGIT; 
LSMEANS ANE HEAl; 
RANDOM UNCTRL; RUN; 
The model results of this analysis are shown in Table 5.16. In Table 5.17, the first 
two measures indicate that the model is statistically significant; and the third one 
demonstrates that the model fits the dataset very well. 
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Table 5.16 Overall Information 
Model Information 
Data Set SASUSER.RMIXW 
-----
Response Variable Renal 
Response Distribution Binary 
Link Function Logit 
Variance Function Default 
Variance Matrix Not blocked 
Estimation Technique Residual PL 
Degrees of Freedom Method Containment 
Table 5.17 Fit Statistics 
Fit Statistics 
------ -
-2 Res Log Pseudo-Likelihood 180738.80 
Generalized Chi-Square 110055.61 
Gener. Chi-Square / DF 11.01 
Covariance Parameter Estimates 
CovParm Estimate Standard Error 
------
Unctrl 8.21 E-22 
Table 5.18 Type 3 Analysis for Fixed Effects 
Type III Tests of Fixed Effects 
Effect NumDF DenDF F Value Pr>F 
Ane 1 9996 3.68 0.0551 
------ t------ ---- ---------
Hea 1 9996 6.77 0.0093 
Table 5.19 Least -square Means Analysis 
Ane Least Squares Means 
Ane Estimate Standard DF t Value Pr> It I 
0 4.7986 0.2116 999 22.67 <.0001 
1 4.0978 0.3677 999 11.14 <.0001 
Hea Least Squares Means 
Hea Estimate Standard DF t Value Pr> It I 
--------1-------I--
0 4.9771 0.1895 999 26.26 <.0001 
1 3.9192 0.4000 999 9.80 <.0001 
82 
Table 5.17 lists the covariance parameter estimates for a random variable. The 
variance for Unctrl is rather small and so the variable is significant to the model. The 
output in the Type 3 analysis (TableS. 18) shows that both anemia and heart disease are 
significant to the model. Table 5.19 lists the information about the least-square means. 
The output shows that the estimate mean for anemia is 4.0978 and the standard error is 
0.3677, while the value for heart disease is 3.9192 and its standard error is 0.4. 
Therefore, the two diseases are almost equally important to renal failure. 
5.4 Conclusion 
After this analysis, we can draw the conclusions that in order to decrease 
Medicare costs, we should often monitor blood glucose level of diabetes outpatients and 
we also should emphasize diabetes prevention. In addition, chronic kidney disease 
affects the charges the most. Finally, we should monitor heart disease and anemia of the 
diabetic outpatients with renal failure. 
In this chapter, we focus on outpatients with diabetes in the Medicare population; 
in next chapter, we will study inpatients with diabetes. 
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CHAPTER VI 
COST ANALYSIS AND OUTCOMES RESEARCH FOR 
MEDICARE INPATIENTS WITH DIABETES 
In the previous chapter, we conducted a cost analysis of diabetes outpatients in 
Medicare. The analyses of inpatients encompass more than those of outpatients. In this 
chapter, based on the inpatient claims data and demographic data from the CMS CCW 
data[ 18], we will start a cost analysis among different races or different complications of 
diabetes; then, we will perform association rule analysis of different procedures. Next, we 
will use various kinds of supervised learning algorithms to study the outcomes and a 
readmission analysis of inpatients and we will end up with two-way interaction effects 
analysis of diabetes complications. 
6.1 Cost Analysis 
6.1.1 Inpatient Costs among Different Races 
At the beginning, we study the general cost distributions among different races 
using kernel density estimation (Figure 6.1). Before the value of 40,000 dollars occurs, 
North American natives> Whites> Blacks> Hispanics in terms of densities for costs, and 
all of them spend more than Asians; while after that point, Asians cost more than the 
other races. 
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Figure 6.1. KDE of Total Charges among Different Races 
6.1.2 Costs among Different Diagnosed Diseases 
In this section, we want to see how different groups of diagnoses affect the costs. 
Before that, we define a string containing all possible diagnosis codes using the CATX 
statement in SAS. 
0.1284052 
0.0362 0.0988086 ... 
0 .1828 0.1266924 ... 
1276 0.1276 0.1260251 .. 
1515 0.1515 0.1 
790 0.079 0.1176632 
Figure 6.2. Clusters of Diagnoses 
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After conducting clustering analysis with the E-M algorithm using SAS Text 
Miner, we get the results displayed in Figure 6.2. To view how the groups of diagnoses 
affect the total charges, we perform kernel density estimation. 
Cluster 
number 
2 
3 
4 
5 
6 
7 
8 
9 
Table 6.1 Translations for the Clusters 
Diagnoses 
Unspecified Obesity, Schizoaffective disorder, Diabetes 
mellitus without mention of complication, Tobacco use 
disorder, Other and unspecified hyperlipidemia 
Old myocardial infarction, Of native coronary artery, 
Aortocoronary bypass status, Of unspecified type of vessel 
or native or graft, Percutaneous transluminal coronary 
angioplasty status 
Other and unspecified angina pectoris, Other specified 
cardiac dysrhythmias, Other persistent mental disorders due 
to conditions classified elsewhere, Of native coronary artery, 
Pure hypercholesterolemia 
Unspecified Essential hypertension, Diabetes mellitus 
without mention of complication, Unspecified 
hypothyroidism, Osteoarthrosis which unspecified whether 
generalized or localized, Depressive disorder 
Diabetes with neurological manifestations, Background 
diabetic retinopathy, Diabetes with ophthalmic 
manifestations, Diabetes with ophthalmic manifestations, 
Other and unspecified hyperlipidemia 
Unspecified Acute renal failure, unspecified Congestive 
heart failure, Obstructive chronic bronchitis with 
exacerbation, Unspecified Hypertensive chronic kidney 
disease, Pneumonia 
Mitral valve disorders, Diabetes mellitus without mention of 
complication, unspecified Congestive heart failure, Other 
primary cardiomyopathies, Atrial fibrillation, 
Alzheimer's disease, Urinary tract infection, unspecified 
Anemia, Volume depletion, Pneumonia 
Diabetes mellitus without mention of complication, 
Esophageal reflux, Other and unspecified hyperlipidemia, 
Unspecified Essential hypertension, Pure 
hypercholesterolemia 
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Cluster label 
Diabetes 
Heart disease 
Heart disease 
vascular disease 
vascular disease 
Diabetes 
Ophthalmic disease 
Neurological disorder 
Heart disease 
Kidneydisease 
Diabetes 
Heart disease 
Others 
Diabetes 
vascular disease 
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Figure 6.3. KDE of Total Charges for Diabetic Inpatients by Clusters (Male) 
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Figure 6.4. KDE of Total Charges for Diabetic Inpatients by Clusters (Female) 
Figures 6.3 and 6.4 demonstrate that the distributions of the costs for male 
inpatients are different from the ones for females. The clusters yield the relationships in 
terms of ordering. For males, before the first cutpoint occurs at 19,200 dollars, in terms of 
density, cluster #5 is much greater than the other clusters; between the cutpoints of 
19,200 dollars and 33,000 dollars, the ordering of estimated density is 1,4, 5,9>2,3>6, 7, 
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8. After 33,000 dollars, there are no differences among all clusters. The graph for female 
inpatients shows the costs in terms of ordering is 9>5>2>1,3>7,8>4,6 before the first 
cutpoint of 10,650 occurs. 
6.1.3 Cost Distributions among Organ Diseases 
The previous analysis indicates that diabetes has many complications such as 
heart disease or renal failure. We will demonstrate the expenditures on these organ 
diseases shown in Figure 6.4. Before that, we need to generate a new variable, ORGAN 
with the following SAS code: 
DATA SASUSER.IPORGAN (KEEP=CLM_CD CLM_TOTO_CHRG_AMT 
DIAGNOSES HEA KID OCULO NEU); SET SASUSER.IPCLAIMDEMO; 
HEA=Oi KID=Oi OCULO=Oi NEU=O; 
DIAGNOSES= CAT X ( , , , ICD9_DGNS_CDl, ... ICD9_DGNS_CD16); 
IF(RXMATCH('4280',DIAGNOSES»0)THEN HEA=l; 
IF (RXMATCH ( , 4254' , DIAGNOSES) >0) THEN HEA=l; ... 
DATA SASUSER.ORGAN; SET SASUSER.IPORGAN; 
IF HEA=l THEN ORGAN=li IF KID=l THEN ORGAN=2; IF OCULO=l 
THEN ORGAN=3i IF NEU=l THEN ORGAN=4i RUN; 
The graphs in Figure 6.5 indicate that before the costs reach the value of 9,900 
dollars, the cost with heart disease, the cost with ophthalmic diseases and the cost with 
neurological disorders have almost the same probability, which is much higher than the 
cost without any of the organ diseases; the probability for the cost with kidney disease is 
the smallest. However, after the cutpoint at 34,350 dollars, the density of the cost with 
kidney disease is higher than any other densities. It shows that kidney disease has the 
highest probability of the highest cost while neurological disorders have the highest 
probability of lowest cost with heart disease and ophthalmic diseases having similar 
probabilities as neurological disorders. 
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Figure 6.5. Costs by Different Organ Diseases 
6.2 Outcomes Research 
6.2.1 Association Rule Analysis of Procedures 
Before we study the outcomes of inpatients, we conduct market basket analysis of 
various procedures and the results are displayed below. Figure 6.6 shows all the major 
connections between different procedures. The procedures shown in table 6.2 are 
important, since all of the rectangular boxes representing those procedures are bigger 
than the others. Among the procedures, five of them are used for cardiac di sease and one 
is related to hematic disease, which form 6 centers of the diagram; they are marked with 
an asterisk, '*' in Table 6.2. 
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Colonoscopy In itial insertion ... atrium and 
ventricle; Initial insertion of dual-
chamber device 
Code 
3601* 
3607* 
3722* 
3772 
3783 
3893 
3895 
3995 
4516 
4523 
Continuous ... ventilation 
Transfusion of packed cells 
8856 & 8853 & 3601 
8858 &3607 &36018856&3722 &360t8858 &3722 &3607 
Figure 6.6. Associations of Procedures 
Table 6.2 Translations for Important Procedures 
Procedure 
Single vessel percutaneous translurninal coronary angioplasty 
Insertion of drug-eluting coronary artery stent(s) 
Left heart cardiac catheterization 
Initial insertion of transvenous leads [electrodes] into atrium and 
Initial insertion of dual-chamber device 
Venous catheterization, not elsewhere classified 
Venous catheterization for renal dialysis 
Hemodialysis 
Esophagogastroduodenoscopy [EGD] with closed biopsy 
Colonoscopy 
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Code Procedure 
8853* Angiocardiography of left heart structures 
8856* Coronary arteriography using two catheters 
9339 Other physical therapy 
9383 Occupational therapy 
9604 Insertion of endotracheal tube 
9671 Continuous invasive mechanical ventilation for less than 96 consecutive 
9672 Continuous invasive mechanical ventilation for 96 consecutive hours or 
9904 Transfusion of packed cells 
9920 Injection or infusion of platelet inhibitor 
Table 6.3 Confidence and Lift for Rules 
Rules Confidence Lift 
(%) 
Initial insertion ... atrium and ventricle==> Initial insertion of dual-chamber device 100 73.22 
Initial insertion of dual-chamber device==> Initial insertion ... atrium and ventricle 97.28 73.22 
Angiocardiography of left heart structures ==> Coronary arteriography 94.17 9.38 
Left heart cardiac catheterization==> Coronary arteriography 
89.92 8.96 
Angiocardiography of left heart structures==> Left heart cardiac catheterization 89.24 9.56 
Coronary arteriography==> Left heart cardiac catheterization 83.64 8.96 
Hem dialysis== > Venous catheterization for renal dialysis 79.61 7.41 
Insertion of drug-eluting coronary artery stent(s)==> Single ... coronary angioplasty 78.68 18.37 
Left heart cardiac catheterization==> Angiocardiography 78.66 9.56 
Coronary arteriography==> Angiocardiography of left heart structures 77.21 9.38 
Insertion of drug-eluting coronary artery stent(s)==> Coronary arteriography 77.16 7.08 
Occupational therapy==> Other physical therapy 77.08 43.06 
Other physical therapy==> Occupational therapy 76.29 43.06 
Continuous invasive mechanical ventilation==> Colonoscopy 
74.27 14.74 
Injection or infusion==> Coronary arteriography 73.27 7.28 
Single ... coronary angioplasty==> Coronary arteriography 
72.84 7.26 
Insertion of drug-eluting coronary artery stent(s)==> Left heart cardiac 
catheterization 71.07 7.61 
Single ... coronary angioplasty==> Left heart cardiac catheterization 68.10 7.29 
Single ... coronary angioplasty==> Insertion of drug-eluting coronary artery stent(s) 
66.81 18.37 
Injection or infusion==> Left heart cardiac catheterization 
64.36 6.89 
Continuous invasive mechanical ventilation more than 96 hour==> Insertion of 
endotracheal tube 63.25 12.55 
Continuous invasive mechanical ventilation more than 96 hour==>Continuous 
invasive mechanical ventilation 56.04 14.74 
Single ... coronary angioplasty==> Angiocardiography of left heart structures 
55.60 6.75 
Insertion of drug-eluting coronary artery stent(s)==> Angiocardiography 
55.33 6.72 
Insertion of endotracheal tube==> Continuous invasive mechanical ventilation more 
than 96 hour 38.46 12.55 
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Table 6.3 just shows the important and meaningful rules; the combination cases 
are not considered. The initial insertion of trans venous leads [electrodes 1 into the atrium 
and ventricle will be used given that the procedure, initial insertion of dual-chamber 
device will be subsequently used. The lift value for this rule is 73.22, which indicates that 
the association between these two separate procedures is strong. For the same reason, the 
relationship between occupational therapy and other physical therapy is also strong. The 
confidence values are higher for the other rules in the table, which indicate that it is very 
likely that subsequent procedures will be used if the antecedent procedure is used, since 
all the left confident values are high. 
6.2.2 Mortality Prediction of Diabetes Inpatients 
One of dominant issues in outcomes research is about mortality. In this section, 
we use various kinds of supervised learning approaches shown in Figure 6.7 with 
mortality as the targeted variable; Age, Gender, Diagnosis Procedures and Diagnosis 
Procedures are identified as the input variables. To predict mortality, we use the 
regression model, the Dmine Regression model, the Neural Network model, the Auto 
Neural model, the Decision Tree model, the MBR model, the Rule Induction model and 
the Model Comparison model; and these nodes are shown in Figure 6.7. Table 6.4 shows 
that the Model Comparison node identifies the decision tree as the optimal model based 
on misclassification rates. 
The ROC maps in Figure 6.8 show that for all three data subsets: Train, Validate 
and Test, there are no big differences in accuracy among the various models. According 
to the lift curves, we can find the patients at highest risk of dying. Figure 6.9 
demonstrates that except for the MBR node, there are no differences among the other 
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nodes in terms of the prediction of mortality. In the train set, validate set and test set, 
40 % of beneficiary records have a higher level of prediction than just chance. 
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Table 6.5 Variable Importance in Tree Targeting at Mortality 
NAME IMPORTANCE VIMPORTANCE RATIO 
PROCLUSTER 
DIACLUSTER 
Age 
Utili zation Day Count 
Total Charge 
1.0000 
0.7254 
0.3845 
0.3364 
0.2466 
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1.0000 
0.6807 
0.3993 
0.3464 
0.2528 
1.0000 
0.9384 
1.0386 
1.0297 
1.0252 
''''' 
Results in Table 6.5 demonstrate that the order of importance in the levels is 
procedures> diagnoses >age > days of staying in the hospital> total charges. The tree 
diagram in Figure 6.10 displays how the input variables affect mortality; the first segment 
is divided on the procedure cluster, indicating that procedures are essential to mortality; 
the next split is based upon the diagnosis cluster. The followin g split criteria vary from 
the left side to the right side. Age has no relation to mortality related to the procedure 
cluster #5 (endotracheal tube and catheterization) and #7 (Some heart operations); for the 
procedure cluster 1 and cluster3 , age is also an important factor. Before the age of 82.5, 
both total charges and utilization day count should be considered, while after th at, only 
utilization day count should be focused on. 
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Figure 6.10. Tree Diagram Aiming at Mortality 
95 
6.3 Readmission Analysis 
Under the current economic circumstances, medical care providers have become 
concerned about readmission rates. In this section, we attempt to find the diabetes 
patients who have higher risks of readmission using Medicare inpatient claims data from 
the CMS CCW data [18]. We first introduce the definition of readmission by CMS; then, 
we use SAS SQL to get the inpatients who re-enter the hospital after discharge within 30 
days and the most frequent diseases and procedures for these patients; before we perform 
supervised learning, we conduct pattern recognition analysis. 
6.3.1 Medicare Readmission 
When defining readmission, different researchers give different definitions. CMS 
defines readmission as the re-entry to the hospital after discharge within 30 days and 
considers it as an important measure of poor quality health care. One report from the 
Atlantic Information Services, Inc. [60] demonstrates that almost 18 % of Medicare 
patients are readmitted within 30 days of discharge and 13% of the readmissions ($12 
billion worth) can be avoided if the correct treatments are provided. Medical providers 
are currently facing pressure to reduce the readmission rate while improving care quality. 
It is with this motivation that we evaluate the readmission risk of diabetic patients. We 
study three kinds of risk factors influencing readmission rates, (1) patient demographic 
information including age, gender, and race; (2) patient disease characteristics such as 
common co-morbidities and procedures for diabetes; (3) medical resources usage such as 
length of hospitalization and discharge locations. 
6.3.2 Data Processing to Find Readmission Inpatients 
In the process of conditionally inner joining the two tables, observations are 
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grouped by patient ID and dates; each group having the property that the differences 
between the discharge date and the readmission date is less than 30 days. The code is: 
PRoe SQL; CREATE TABLE SASUSER . AD AS 
SELECT Tl .BENE_ID , Tl . CLM_ADMSN_DT ,T l . NCH_BENE_DSCHRG_DT , 
DATDIF(Tl . NCH_BENE_DS CHRG_DT , MIN(T2 . CLM_ADMSN_DT) , ' ACT/ACT ') 
AS DATEDIF , MIN (T2 . CLM_ ADMSN_DT) FORMAT=DATE9 . AS MINAD 
FROM SASUSER . QRDM2010 AS T1 
INNER JOIN SASUSER . QRDM2010 AS T2 
ON Tl . BENE ID=T2 . BENE 10 AND 
Tl . CLM_ADMSN_DT<T 2 . CLM_ ADMSN_DT AND 
T2 . CLM_ADMSN_DT>Tl . NCH_BENE DSCHRG_DT 
WHERE Tl . NCH_BENE DSCHRG_DT IS NOT NULL AND Tl . CLM_ADMSN_DT 
IS NOT NULL GROUP BY 
Tl . BENE_ID , Tl . CLM_ADMSN_DT , Tl.NCH_BENE_DSCHRG_DT 
HAVING DATDIF (T l .NCH_BENE_DSCHRG_DT, MIN(T2 . CLM_ ADMSN_DT ) 
, ' ACT/ACT ') <=30 ORDER BY DATEDIF i QUITi 
6.3.3 Pattern Recognition 
We first conduct pattern recognition analysis using the cluster node in Enterprise 
Miner with the hierarchical clustering algorithm. 
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Figure 6.14. Demographic Characteristics of Patients Having Cardiovascular Procedure 
Some results shown in Figures 6.11 - 6.14 gi ve us a rough description of the 
inpatients. The patients are segmented by 5 age groups. In Figure 6.11, the x-axis, the y-
axis and the z- axis stand for CVD (Cardiovascular Disease), gender and admission 
frequency respectively. It is the same for the other graphs. Generally, as Figures 6.11-
6.12 and 6.14 demonstrate, there is no obvious difference in frequency of hospitalization 
in different age groups for those patients who have cardiovascular disease or renal 
disease or have procedures related to these diseases. However, the patients who have 
heart disease are more likely to be admitted to the hospital than those who do not and this 
difference can be seen in the axis representing CVD in Figure 6.11. Figure 6.14 indicates 
that the male patients who receive heart procedures have a higher possibility of 
readmission compared to female patients. When comparing Figures 6.11- 6.12 to Figure 
6.13, we can also conclude that in most cases, the patients with cardiovascular 
disease or kidney disease have a higher risk of readmission after discharge compared 
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to those with other diseases such as digestive disorder. 
6.3.4 Supervised Learning with Readmission as the Target 
In the following analysis, we need a more accurate estimate of the readmission 
risk; then, we will perform supervised learning. First, we combine the patients who 
readmitted to the hospital with the other inpatients and define a new variable, RA for 
readmission risk. 
Next, we utilize the code displayed below to find out the top 20 most frequent 
procedure codes for the patients readmitted and apply a similar method to get the top 20 
diagnosis disease codes. The most common co-morbidities are heart disease, kidney 
disease, digestive disorder and respiratory disease and the most frequent procedures are 
those related to the above diseases. Therefore, we apply the CATX, 0-1 indicator and 
RXMATCH functions to define the new predictors such as CVD (Cardiovascular disease) 
and PKD (Procedures related to kidney diseases) with the SAS code: 
/*put all procedures into one column*/ 
PROC SQL;CREATE TABLE SASUSER.PR004 AS 
SELECT BENE_ID, ICD9_PRCDR_CDl AS PRO FROM SASUSER.RD04 
WHERE ICD9_PRCDR_CDl IS NOT NULL UNION 
SELECT BENE_ID, ICD9_PRCDR_CD2 AS PRO FROM SASUSR.RD04 
WHERE ICD9 PRCDR_CD2 IS NOT NULL ... 
/*find the freq of procedures*/ 
CREATE TABLE SASUSER.COUNT AS 
SELECT PRO, COUNT(*) AS C FROM SASUSER.PR004 
GROUP BY PRO ORDER BY C DESCEDING; QUIT; 
For a precise prediction, we utilize the variable selection node in SAS Enterprise 
Miner 6.2 to select the prominent input variables by R2 shown in Figure 6.15. 
Considering the large data sample, we choose the variables with R2 greater than 0.1 and 
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they are patient discharge location, Medicare status, diabetes, kidney disease, length of 
stay in the hospital, respiratory disease and procedures related to kidney dysfunctions. 
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Figure 6.16. Various Predictive Models 
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Now, we can use different models such as the decision tree models (with the 
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default method or with the CHArD algorithm), the logistic regression model and the 
neural network model to predict readmission risk. Figure 6.16 shows the process flow. 
Table 6.6 Important Variables to Readmission Estimation 
Variable name Number of splitting rules Importance 
Discharge places 
Medciare status 
Diabetes 
Length of hospitalization 
Kidney disease 
Respiratory di sease 
Procedures related to kidney diseases 
2 
3 
o 
&1.51.. 
I 
0.74 
0.48 
0.41 
0.33 
0.22 
o 
Discharge place code 0 I :home; 02: short term general hospital ; 03:skilled nursing facility; 06:home 
health service; 30: still patient; 51 hospice - certified medical facility ;62: inpatient rehab facility; 
63:Medicare certified long term care hospital. 
Figure 6.17. Tree Diagram with CHAID for Readmission 
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The model comparison node chooses the decision model with the CHAID 
algorithm as the optimal model. The outputs shown in Table 6.6 demonstrate that patient 
discharge places, patient status (old or old with end stage renal failure), LOS (length of 
stay in the hospital), kidney disease and respiratory disease are key factors to predict 
readmission rate. In the above tree diagram (shown in Figure 6.17), such organizations as 
a short term hospital, a skilled nursing facility and a Medicare-certified long term care 
hospital can provide professional medical services while the other organizations do 
not. The diagram indicates that the inpatients who are discharged to home or hospice 
have a higher readmission rate than other patients. 
6.4 Two - way Interaction Effects of Diabetes Complications 
In the previous sections, we discussed the key factors to costs and outcomes 
without considering the interactions between each factor. In this section, we will analyze 
the two-way interaction effects of diabetes complications such as cardiovascular disease 
and hypertension on Medicare expenditures and health outcomes such as frequency and 
length of hospitalization. For two factors, A and B, two - way interaction effect analysis 
reflects whether a level of effect of factor A is influenced by a level of effect of factor B. 
An interaction plot can simply and vividly demonstrate the interaction, but in most cases, 
these interactions need statistical demonstration. 
6.4.1 Data Processing 
In order to get the data ready for our analysis, we process the data in the following 
steps. 
• Conditionally inner join the two data sets, inpatient claims data and beneficiary 
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demography data by beneficiary ID. 
• Use random sampling to reduce the data size from 244,299 records to 40,000 
claims. 
• Use the proc means procedure to get the average costs, average days in the 
hospital and total times of entering the hospital for each beneficiary ID (Each 
patient in Medicare has hislher own unique beneficiary ID). 
• Utilize the CATX function, RXMA TCH function and 0-1 indicator functions to 
generate binary variables, common diabetes complications and they are Hea 
(Heart disease), Kid (Kidney disease), Eye (Eye disease), Neu (Neurologic 
disease) and Hyper (Hypertension). 
• When we develop the logistic regression model to predict mortality, we apply 
overs ample to guarantee that all the observations of mortality are included in the 
sample and we use the following SAS code: 
PROC SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.LOGISTIC; 
BY STATUS; RUN; 
PROC SURVEYSELECT DATA=SASUSER.LOGISTIC 
OUT=SASUSER.OVERSAMPLE 
SEED = 39585784 SAMPSIZE = 1256; 
STRATA STATUS; RUN; 
Now we get what we want and we can perform our analysis in the following 
sections. 
6.4.2 Two - way Interaction Effects of Diabetes Complications on Cost 
We start our study with cost analysis. In order to examine whether there exist 
significant two-way interaction effects between diabetes complications, we firstly plot 
interaction effects on Medicare payments. We use the following SAS code and the 
lO4 
similar codes for the other interaction effects plots .The variables are explained in 
Table 6.7. 
PRoe SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.NEW1; 
BY HEA_MAX HYPER_MAX; RUN; 
PROe MEANS DATA=SASUSER.NEW1; 
VAR CLM_PMT_AMT_MEAN; BY HEA_MAX HYPER_MAX; 
OUTPUT OUT=SASUSER.NEW2 MEAN=CLM_PMT_AMT_MEAN;RUN; 
SYMBOL VALUE=DOT I=JOIN;PROe GPLOT DATA=SASUSER.NEW2; 
PLOT CLM_PMT_AMT_MEAN * HEA_MAX = HYPER_MAX; RUN; 
Table 6.7 Explanations for Variables 
Variable 
CLM]MT_AMT_MEAN 
HEA_MAX 
HYPER_MAX 
OCULO_MAX 
NEU_MAX 
Explanation 
A verage payments for each patient 
Heart disease 
Hypertension 
Eye disease 
Neurological disease 
An interaction effect plot gives a general estimation whether an interaction effect 
is significant and how the two different factors influence each other. The rule [611 is that 
if the two lines (representing the two levels of one factor) do not cross and are not 
parallel to each other, then the effect is significant. The difference of two levels of one 
factor indicates the main effect of the other factor. If the two lines interact with each 
other, the interaction effect is still significant, but the main effect should not be 
considered. 
To be specific, let us look at the plots in Figure 6.18. These plots demonstrate 
some interactions between different diseases with Medicare payments as a response 
variable and they are significant according to the stated rule. Consider kidney disease, for 
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example; its interaction effect with a neurological disorder is significant and for diabetes 
inpatients with kidney disease, there is a big difference on their costs between the case 
when they have a neurological disorder and the case when they do not. 
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Figure 6.18. Interaction Effects on Costs Plots 
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However, the above plots just provide a basic idea; we need to use statistical 
models to further prove the significance of the interaction effects. We input the variables 
listed in Table 6.7 and their two-way interaction as predictors into the generalized linear 
model with a gamma distribution and use Medicare payments as the response variable, 
then we get the type III analysis results shown in Table 6.8. The table shows that without 
considering main effects, only these interaction effects are significant in the model of 
Medicare payments and they are: interaction between heart disease and kidney disease, 
interaction between heart disease and hypertension, interaction between kidney disease 
and neurological disease, interaction between kidney disease and hypertension, 
interaction between eye disease and neurological disease, and interaction between eye 
disease and hypertension since all of their p-values are smaller than the significance level 
0.05. 
Table 6.8 Type 3 Analysis for Interaction Effects(Cost) 
Wald Statistics For Type 3 Analysis 
Source DF; Chi·Square Pr> ChiSq 
Hea_Max*Kid_Max 1 22.64 <.0001 
Hea_Max*hyper_Max 1 i 
I 
25.86 <.0001 
Kid_Max*Neu_Max 11 17.96 <.0001 
Kid_Max*hyper_Max 1 ! 10.66 0.0011 
Oculo_Max*Neu_Max 1 7.76 0.0053 
r-- "~~-------c--- ------ ~~ ~-
Oculo_Max*hyper _Max I. 12.11 0.0005 
6.4.3 Two - way Interaction Effects on Length of Hospitalization 
In this section, we discuss the influence on length of stay (LOS) in the hospital. 
From this section on, we will directly investigate the effects with statistical models 
without demonstrating interaction plots. Because LOS also follows a gamma distribution 
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and has similar properties to Medicare payments, we use the generalized model with a 
gamma distribution. Table 6.9 displays the significant interaction effects. It demonstrates 
that for patients with other complications, the fact that they have kidney disease or not 
makes their LOS different. This conclusion is also true for hypertension. 
Table 6.9 Type 3 Analysis for Interaction Effects (LOS) 
LR Statistics For Type 3 Analysis 
Source DF Chi-Square Pr> ChiSq 
Hea_~ax*hyper-~ax 1 38.37 <.0001 
Kid_~ax*Oculo_~ax 1 3.99 0.0458 
Kid_~ax*Neu_~ax 1 11.03 0.0009 
--- f------ -----~---
Kid_~ax*hyper-~ax 1 3.88 0.0487 
Neu_~ax*hyper-~ax 1 8.40 0.0038 
Oculo_~ax*hyper_~ax 1 10.55 0.0012 
6.4.4 Two - way Interaction Effects on Frequency of Hospitalization 
In this section we will discuss the interaction effects on frequency of 
hospitalization, i.e., the average times of hospital stay for each patient. Since the 
frequency is a count variable, we assume that it follows a Poisson distribution. Therefore, 
we apply a Poisson regression model for our analysis. In order to adjust the over-fitting of 
this model, we set "scale = Pearson" and the SAS code is shown below. 
PROC GENMOD DATA=SASUSER.INTERACTIONNEW; 
CLASS Hea~Max Kid~Max Oculo~Max Neu~Max hyper~Max; 
MODEL COUNT= Hea~Max*Kid~Max ... hyper~Max/ 
LINK=LOG 
DIST=POISSON 
SCALE=PEARSON 
TYPE3; 
LSMEANS Hea~Max*Kid~Max ... / ALPHA=O. 05; RUN; 
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The scaled deviance and the scaled Pearson X 2 (Table 6.10) indicates that the 
model fit the data relatively well. Table 6.11 (Only significant interaction effects left in 
this table) demonstrates that for the patients with other diseases, there is a big difference 
in the frequency of being admitted to the hospital between the patients who have heart 
disease and those who do not. 
Table 6.10 Goodness Fit of Poisson Regression model 
Criteria For Assessing Goodness Of Fit 
Criterion DF Value ValuelDF 
Deviance 34E3 4517.0538 0.1327 
~- --
Scaled Deviance 34E3 26557.3993 0.7803 
Pearson Chi-Square 34E3 5788.5522 0.1701 
Scaled Pearson X2 34E3 34033.0000 1.0000 
Table 6.11 Type 3 Analysis for Interaction Effects (Frequency) 
LR Statistics For Type 3 Analysis 
Source NumDF DenDF F Value Pr>F Chi-Square Pr> ChiSq 
Hea_Max*Kid_Max I 34033 34.45 <.0001 34.45 <.0001 
Hea_Max*Oculo_Max I 34033 7.79 I 0.0052 7.79 0.0052 
Hea_Max*Neu_Max I 34033 6.99 0.0082 6.99 0.0082 
Hea_Max*hyper_Max I 34033 50.57 <.0001 50.57 <.0001 
Kid_Max*Neu_Max I 34033 24.67 
I 
<.0001 24.67 <.0001 
, 
Kid_Max*hyper_Max I 34033 121.91 i <.0001 121.91 <.0001 
6.4.5 Two - way Interaction Effects on Mortality 
In the last section of two-way interaction effects, we will analyze the effects on 
the mortality of inpatients with diabetes. Mortality is a rare occurrence event because the 
patients who are dead only account for 4.5% in the whole inpatient population. Hence, in 
order to get an objective result, we need to overs ample those patients. We stratify 
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STATUS into two classes, dead or alive; then, we sort the data by STATUS and perform 
stratified sampling, setting sample size to be 1256 (the total number of the deaths in a 
sample with a size of 40,000 claims) and selecting the same number of patients alive. The 
code is shown below. 
PROC SORT DATA=SASUSER.INTERACTIONNEW OUT=SASUSER.LOGISTIC; 
BY STATUS; RUN; 
PROC SURVEYSELECT DATA=SASUSER.LOGISTIC 
OUT=SASUSER.OVERSAMPLE 
SEED = 39585784 SAMPSIZE = 1256; 
STRATA STATUS; RUN; 
Once we get the data ready, we perform logistic regression analysis with the 
binary variable, STATUS as the dependent variable and the stepwise selection method to 
choose the best model. The selection process only proceeds to the second step and then 
stops, since no effect in the model can be removed and no additional new effect meets the 
requirement of entering the model. The R-square of this model is 13 %; considering the 
large data size, it is a reasonable fit, but it still means that 87% of the variability in the 
outcome variable remains unaccounted for. Table 6.13 demonstrates that the two -way 
interaction effects between heart disease and kidney disease or the interaction effects 
between neurological disease and hypertension are significant in the model. 
Table 6.12 R-square for Logistic Regression Model 
Table 6.13 Type 3 Analysis for Interaction Effects (Mortality) 
Type 3 Analysis of Effects 
Wald 
Effect DF Chi-Square Pr> ChiSq 
Hea_Max*Kid_Max I 14.9807 0.0001 
Neu_Max*hyper_Max I 7.9346 0.0048 
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6.5 Conclusion 
Cost analysis of inpatients shows that many organ diseases and neurological 
disorders indeed have decisive effects on the costs of inpatients with diabetes: heart 
disease, eye disease and nervous system diseases raise the inpatients costs. The results 
demonstrate that under a threshold amount of costs, kidney disease does not impact the 
expenditures of inpatients as much as the other organ diseases do; however, as the costs 
increase, the effects of kidney disease become more and more important. Hence, all 
inpatients with diabetes should pay more attention to kidney disease, and use prevention 
to avoid such diseases to decrease the costs. 
Outcomes research demonstrates that among the various procedures, the ones 
utilized for cardiac disease treatments are related to many different procedures. 
Association analysis also shows that hemodialysis is strongly related to venous 
catheterization for renal dialysis. Another discovery is that the procedures and the 
diagnoses are decisive to predicting mortality, which is contrary to widely held belief. 
Through this readmission study, we can conclude that the following kinds of the 
Medicare diabetic inpatients have a high risk of readmission, those who have 
cardiovascular disease, kidney disease or those male patients who receive procedures 
related to heart disease or those who do not get professional medical care after discharge. 
Therefore, in order to decrease readmission risk, we should take greater care of these 
kinds of patients. This care might need to include a higher level of reimbursement from 
Medicare. 
Two-way interaction effect analysis is carried out to study the interaction effects 
between various diabetes complications on Medicare payments, length and frequency of 
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hospitalization and mortality. Results show that the most interaction effects are 
significant to costs, while only the interaction between heart disease and other diseases 
are significant to the frequency of hospitalization. Another discovery is that kidney 
disease or hypertension has an important influence on the other complications as for 
length of stay in the hospital. We also find that the interaction between heart disease and 
kidney disease has a decisive effect on mortality. 
We have finished studying outpatients and inpatients, and we will investigate the 
influence of Medicare, Part 0 on diabetes medications in chapter VII. 
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CHAPTER VII 
INFLUENCES OF MEDICARE, PART D 
Medicare, Part 0 is the optional prescription drug program. It uses competing 
private plans to provide beneficiaries access to appropriate drug therapies. In the recently 
approved healthcare law, the provisions about this plan were also amended. In this 
chapter, we will estimate the influences of Medicare, Part 0 since its implementation in 
2006 on diabetes medications from usage and cost-effectiveness perspectives as well as 
on diabetes beneficiaries' health status. Our analyses are based on the MEPS data [19], 
which cover information about physician visits, inpatients, prescription drugs and 
demographic information for the year 2005 and the year 2006. The chapter is organized 
as follows: first, the theories related to survival analysis and cost-effective analysis are 
introduced, then the impacts of Medicare, part 0 on the usage of diabetes medications are 
addressed; finally the influences on the cost-effectiveness of the drugs are presented. 
7.1 Basic Theories and Concepts 
7.1.1 Survival Analysis 
Survival analysis [62] is applied to study the occurrence and timing of events 
using statistical methods. It is very useful in studying the events in social and natural 
sciences, such as the onset of disease, births and death. In our research, we will utilize 
survival analysis to find the first switch of medication. 
113 
1. Censoring 
Censoring is an important element in survival analysis, which distinguishes this 
analysis from other statistical methods. Censoring can be counted as an incomplete 
observations issue and it has three forms: left censoring, right censoring and interval 
censoring and two types: type I censoring, type II censoring and random censoring as 
follows: 
• Left Censoring: An observation on a variable T is said to be left censored if Tis 
only known when it is smaller than a value fl. 
• Right Censoring: An observation on a variable T is said to be right censored if Tis 
only known when it is greater than a value f2. 
• Interval Censoring: An observation on a variable T is said to be interval censored 
if T is known when it belongs to the interval [f/, t2]. 
• Type I censoring occurs when the values fl. t2 are fixed. 
• Type II censoring occurs when observation is terminated after a pre-specified 
number of events have occurred. 
• Random censoring occurs when the time of censoring and the survi val 
time are independent. 
In our research, we employ left censoring and type I censoring to study drug 
usage. We set the end of one year as the censored time; and if some drug user does not 
switch the drug to another, then the drug is said to be left censored. 
2. Descriptions 
In this part, we discuss the two standard approaches of describing survival 
analysis: (l) survival function, (2) hazard function. 
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(1) Survival Function: It is defined as the probability that an individual survives longer 
than t, 
s(t) = peT > t) = 1- F(t) (7.1) 
in which F(t) is a cumulative distribution function of variable I. If the event of interest is 
a medicine switch, then the survivor function gives the probability that the drug remains 
to be used beyond time t. 
(2) Hazard Function: If a variable under survival analysis is continuous, then the hazard 
function is preferred and it is defined as: 
p(t ::; T ::; t + ~tlT ~ t) 
h(t) = lim-------'---
ru-.o ~t 
(7.2) 
The importance of this function lies in its interpretations. If the occurrence of an event 
can be repeatable, then the hazard gives an idea about the number of events per interval 
of time. For a non-repeatable event such as death, its reciprocal tells how much time is 
left before the event occurs. 
3. Estimation of Survival Functions 
The estimation of survival functions is a traditional approach including the KM 
(Kaplan- Meier) method and the life table method. Due to the large data set, we prefer the 
latter method, in which the survival estimate is obtained by calculating the conditional 
probabilities of surviving beyond time t, defined by 
i-I ;-1 
Set) = nO-qj) = nPj (7.3) 
j=1 j=1 
For each time interval i, I; is the start time, qi is the conditional probability of failure and 
Pi is the conditional probability of surviving to Ii or beyond that time. 
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7.1.2 Cost Effectiveness Analysis 
Policy makers want to spend fewer dollars while achieving greater treatment 
effects. Cost effectiveness analysis, a newly-emerged method in health economics or 
pharmacoeconomics, can help those people realize their goals. In this section, we will 
briefly introduce the essential concepts, theories and methods used in this methodology. 
1. Basic Concepts 
Before discussing the theories, several concepts [63, 64] should be considered. 
• Health Intervention: This can refer to a treatment, test, or primary prevention 
technique, which is used to improve patients' health status or decrease mortality. 
• Health Status: If we define a specific state of health, for instance, reducing pains, 
as a health state, then a health status is the sum of health states. Typically, there 
are six levels, from pretty healthy to dead shown in Table 7.1. 
• QAL Y (Quality-Adjusted Life Year): It is a measure to estimate quantity and 
quality of life generated by healthcare interventions. QAL Y can be calculated as 
follows: 
QALY = Weight of Health Status * Life Expectanc.v (7.4) 
In the above equation, weight of health status is defined by researchers. We 
define these weights in Table 7.1. Life expectancy is how many years left for a 
person before s/he dies and it can be looked up in a life table [65]. 
• ICER (Incremental Cost Effectiveness Ratio): It is the most frequently-used and 
most important element in health economics, which distinguishes it from other 
kinds of economics. It is typically defined as a ratio of difference in costs to 
differences in effects of interventions, shown in (7.5). 
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ICER= (costnew - coStold) / (effectnew - effectold) (7.5) 
leER indicates the additional costs required to generate one unit of effect. The 
effect is usually measured by QAL Y, and the cost is measured in currencies. 
leER is used to compare two treatments or two drugs on the same patients in 
clinical trials, but we apply it to compare two cases for the two years for the same 
drug treatment with the same patients. 
Table 7.1 Weights of Health Status 
Level of Health Status Weight 
Pretty Healthy 
Healthy 
Relatively Healthy 
III 
Severely III 
Dead 
2. Common Methodologies 
0.8 
0.6 
0.4 
0.2 
o 
In cost effectiveness analysis, two kinds of models [661 are often utilized. One is 
the decision tree model, different from what we discussed in the previous chapters. The 
tree model must first be split on two interventions, and then each intervention node is 
split into several sub-trees about costs and outcomes with corresponding probabilities. 
The other is a Markov model, assuming that there are finite numbers of defined health 
states, and at any time, each patient should be assigned to one health state. At the end of 
each state, the patients can be shifted from one state to another state with a certain 
probability. Another approach is one-way sensitivity analysis [67] , in which one variable 
is chosen to change values and the other variables are kept constant each time; the leER 
are calculated to see whether the parameter is sensitive or not. 
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3. Our Approach 
In part 2, we introduced several common methods; however, they are not suitable 
for our studies. Instead, we apply medical resources usage analysis. 
In the following section 7.2, we will investigate the impacts on diabetes 
medications using survival analysis; in section 7.3, we will examine the effects on the 
cost effectiveness of drugs and patient health. 
7.2 Impacts of Medicare, part D on the Usage of Diabetes Medications 
In this section, apart from survival analysis, we also perform summary statistics 
and kernel density estimation to understand the impacts better. 
7.2.1 Summary Statistics 
We use Summary Statistics to get the average Medicare payment and the average 
total payment. For comparison, the average Medicare payment in 2005 is expressed in 
2006 dollars with 2005 data inflated based on the CPI-U (Consumer Price Index for all 
Urban Consumers) for prescription drugs [68]. That is to say, once we get the mean 
values for the year 2005, we mUltiply them by the index 1.043. To demonstrate this 
conversion, we put an asterix on the right upper comer of '2005' in Table 7.2. 
Table 7.2 Average Overall Payment and Medicare Payment in 2005 & 2006 
Year Variable Mean N 
2005* SUM OF PAYMENTS 501.66 1759 
MEDICARE (IMPUTED) 20.58 1759 
2006 SUM OF PAYMENTS 558.11 1994 
MEDICARE (IMPUTED) 129.02 1994 
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05 Average Diabetes Medications 
Expectation 
06 Average Diabetes Medications 
Expenditures 
Figure 7.1. Pie Charts of Payments in 2005 &2006 
Table 7.2 and Figure 7.1 show that the average of total payments for the 
prescription increases approximately 12 % from the year 2005 to the year 2006, while the 
average Medicare payment in 2006 is 6 times as much as that in 2005 . The ratio of the 
average Medicare payment to the total expenditures also increases from 4 % to 23 %. 
Results demonstrate that the plan, Part D, indeed increases Medicare drug expenditures. 
7.2.2 Kernel Density Estimation among Diffe rent Clusters of Drugs 
Next, we want to see how Medicare payments are distributed among different 
groups of drugs. We compare Medicare payments in two cases , the general case and the 
Medicare case in which the beneficiaries join Medicare. We need to preprocess the data 
sets. First, we convert the variable, NRXNAME, into observations by the transpose 
procedure, the trim function, the translate function and the concatenation operator. The 
SAS code [26] is shown below. 
PROC SORT DATA=SASUSER.SMED06 OUT=SASUS ER . SORTMED06 ; 
BY DUPERSID NRXNAME; RUN; OPTIONS OBS=MAX ; 
DATA SASUSER. SORTMR06 ; SET SASUSER . SORTMED06 ; 
NRXNAME= TRANSLATE (LEFT (TRIM (NRXNAME) ), '_',' ' ) ; RUN ; 
PROC TRANSPOSE DATA=SASUSER . SORTMR06 OUT=SASUSER . TRANMR06 
PREF IX=MED_ ; VAR NRXNAME; BY DUPERSID ; RUN ; 
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DATA SASUSER . CONMR06 (KEEP= DUPERS1D SSNRXNAME) ; 
LENGTH SSNRXNAME $ 32767 ; SET SASUS ER . TRANMR 06 ; 
ARRAY CONCAT MED_ :; SSNRXNAME =LEFT(TR1M(MED_l )) ; 
DO 1=2 TO D1 M( CONCAT) ; SSNRXNAME=LEFT( TR1M (SSNRXNAME)) 
I I I I I I LEFT (TRIM (CONCAT[1] )) ; END; RUN; 
(1) General Case: 
After we get the clusters shown in Figures 7.2 & 7.3 using SAS Text Miner, each 
cluster is explained in Tables 7.3 & 7.4; we can do kernel density estimation on Medicare 
payments by clusters . 
. Clusters 
[O[ Descri~ive Terms l~[ Percentage l[ RMS std. 1 
'1 glyburide, rosigl~azone , precose, metformin, glyburide·metformin 271 0.154328018 ... 0.07"11406 ... 
2 glyburide·metformit\ + supply I ~ar lix, precose, prandin 493 0.280751708 ... 0.11 98462 ... 
3 insulin I piogl~azone, + supply I ~arlix , prandin 237 0.134965831 ... 0.0374267 ... 
4 metformin, glimepiride, tolazamide, prandin, rosigl~azone 494 0.281 321'184.. . 0.0838507... 
5 glipizide I rosigl~azone I precose I siarlix I metforrnin 261 0:148633257.. . 0.0693840 ... 
Figure7.2. Clusters of Drugs in 2005 
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· Clusters 
[O[ Descriptive Terms ) ~ [ Percentage )[ RMS std. 
1 glyburide·mejlormin I glimepiride I starlix I insulin I prandin 214 0:10896'1303 ... 0.2865909 ... 
2 + supply I glirnepiride 358 0.182281 059 ... 0.0148972 ... 
3 glyburide I rosiglrrazone I precose I glyburide·melformin I melformin 272 0.1 3849287'1 ... 0.0554535 ... 
4 insulin I + supply I starlix, precose, glyburide·melformin 228 0.1'1608961 3 ... 0.0484771 ... 
5 tolazamide, metformin, glimepiride, prandin, precose 61 '1 0.311 099796 ... 0.0897675 ... 
6 glipizide I rosiglrrazone I pioglrrazone I precose I melformin 28'1 0.143075356 ... 0.0510506 ... 
Figure 7.3. Clusters of Drugs in 2006 
Table7.3 Explanation for Clusters in 2005 
Cluster # Label 
Metformin , Glyburide and their combination 
2 Supplies 
3 Insulin, Supplies 
4 Metformin, Glimepiride 
5 Metformin, Glipizide 
Table 7.4 Explanation for Clusters in 2006 
Cluster# Label 
Insulin , Glyburide-metforrnin 
2 Supplies 
3 Glyburide, metformin and their combination 
4 Insulin , Supplies 
5 Metformin , Glimepiride 
6 Metformin , Glipizide 
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Figure 7.4. Kernel Density Estimation for Medicare in 2005 
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Figure 7.5. Kernel Density Estimation for Medicare in 2006 
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Figure 7.4 demonstrates that most Medicare payments for diabetes medication 
are fewer than 200 dollars. For males, most costs of the drugs are lower than 50 dollars. 
The only exception is cluster 1, which indicates that Medicare pays more for metformin 
and glyburide, and their combination. For female patients, the densities of clusters #2 and 
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#4 are higher than those of the other clusters under 50 dollars; after that, the density of 
cluster 3 is the highest. Hence, female patients spend more on insulin and supplies. In 
2006, the ordering for males' expenditures is cluster# 2 > #5> #6>#1>#3 under 120 
dollars; after the threshold point, the densities for clusters #1 and #3 become higher than 
the others. Women spend much more on clusters #2 and # 5 of the drugs under 140 
dollars, indicating that metformin and supplies cost females more than the others do. 
Hence, most Medicare expenditures are on supplies, metformin and glyburide. 
(2) Medicare Case 
Figures 7.6 and 7.7 show that in 2006, with the Part D introduction into Medicare, 
the expenditures on drugs are greatly increased. The costs of the diabetes supplies, 
metformin and insulin remain higher than the other costs. 
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Figure 7.6. Kernel Density Estimation of 2005 Medicare 
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Figure 7.7. Kernel Density Estimation of 2006 Medicare 
7.2.3 Association Analysis 
In this section, we use the association node in EM 5.2 to get the link graphs for 
relationship analysis of diabetes oral medications. In each graph, each square stands for a 
drug; those drugs which are connected to many different drugs form centers and are 
important in diabetes treatment. The link graphs are displayed in Figures 7.8-7.11. 
'\i""LI~H'UUH 
Figure 7.8. Link Graphs for the Drugs in 2005 (General Case) 
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Figure 7.9. Link Graphs for the Drugs in 2005 (Medicare Case) 
Figure 7.10. Link Graphs for the Drugs in 2006 (General Case) 
.UPP'UI!!i!I! .. tfe,,,,,n 
Figure7.ll. Link Graphs for the Drugs in 2006 (Medicare Case) 
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In this analysis, we also discuss the general case and the Medicare case. In 2005 
in general case (shown in Figure 7.8), diabetes supplies and metformin were two centers 
of the graphs. Insulin has a strong relationship to supplies, although it is not related to the 
other factors. Glyburide, and glipizide are also fundamental. When we study the 
beneficiaries who get their drugs paid by Medicare (shown in Figure 7.9), metformin 
becomes more prominent and it is strongly related to glyburide and glipizide. In 2006, the 
general case (displayed in Figure 7.1 0) remains almost the same except that the supplies 
are connected to the combination of insulin and metformin. In the Medicare case 
(displayed in Figure 7.11), there are fewer connections between different drugs. Figure 
7.11 indicates that if insulin is prescribed, then the supplies are very likely to be 
prescribed, too. Also, once the combinations of the supplies with glyburide are used, then 
metformin will probably be utilized. 
7.2.4 Survival Analysis 
Finally, we perform survival analysis by the life test procedure. For a better 
comparison, we also need physician visit information in 2005. For the year 2006, we 
process the missing time information using the following SAS code and then sort out the 
records for the year 2006 to get the data set shown in Figure 7.12. 
PROC SQL; 
CREATE TABLE SASUSER.SMRS06 AS SELECT SRSMED06.DUPERSID, 
SRSMED06.RNRXNAME, (( CASE WHEN -1 = SRSMED06.RXBEGDD THEN 1 
WHEN -8 = SRSMED06.RXBEGDD THEN 1 WHEN -9 = 
SRSMED06.RXBEGDD THEN 1 ELSE SRSMED06.RXBEGDD END)) AS 
RXDD, 
((CASE WHEN -1 = SRSMED06.RXBEGMM THEN. WHEN -8 = 
SRSMED06.RXBEGMM THEN. WHEN -9 = SRSMED06.RXBEGMM THEN. 
ELSE SRSMED06.RXBEGMM END)) AS RXMM, 
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(( CASE WHEN - 1 = SRSMED06 . RXBEGYRX THEN 2006 WHEN -14 = 
SRSMED 06 . RXBEGYRX THEN 2006 WHEN - 7 = SRSMED06 . RXBEGYRX 
THEN 2006 WH EN -8 = SRSMED06 . RXBEGYRX THEN 2006 WHEN -9 
SRSMED06 .RXBE GYRX THE N 2006 ELSE SRSMED06 . RXBEGYRX END )) AS 
RXYY 
FROM SASUSER . SRSMED06 AS SRSME D06 WHERE CALCULATED RXYY = 
2006 i QUIT i 
Next, we suppress the data by removi ng the repeated information and the SAS 
code is as follows: 
1 
2 
3 .. 
5 
S 
7 
8 
9 
10 
PROC SORT DATA=SASUS ER . SMRS06 OUT=SASUS ER . UNISMRS06 
NODUPKEYi BY DUPERSID SSNRXNAMEi RUN i 
DUPEASID SSNRXNAME RXDD RXMM 
30078019 
" 3012101 2 GLiPIZID E 
3014901 0 METFORMIN 
." .~. 
30177026 GLiPIZIDE 27 12 
. .. . ... -....... -.. 
30177026 · METFORMIN 27 n 
., .. ~. '·1· 
30180024 · GLYBURIDE 1 . .. . ... 
3019201 2 · METFORMIN 20: 
30206025 GLi MEPIRIDE 1 .. , _ .. , ~ 
30217015 · GLYBURIDE 1 : 2 .... " .... .c. 
3030001 3 · METFORMIN 30· 8: 
Figure 7.12. Diabetes Medication in 2006 
RXYY 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
2006 
Next, we convert the date into a SAS date by using the MDY function, transpose 
the data by NRXNAME and DATE and finally merge the two new data sets to get the 
data displayed in Figure 7.13. 
DATU 
2 301 2101 2 GLiPIZIDE 
3 30149010 DATE METFORMIN 
4 30177026 DATE GLiPIZIDE MET FORM IN 17162 17162 
5 30180024 DATE GLYBURIDE 
6 30192012 DATE METFORMIN 16821 
1 30206025 DATE GLiMEPIRIDE 
8 30217015 DATE GLYBURIDE 16833 
9 30300013 DATE METFORMIN 17043 
10 30363015 DATE GLiPIZIDE 
Figure 7.13 . Analysis Data in 2006 
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Next, we search for the first switching of the drugs and define the variable, 
STATUS. During the analysis, we make some assumptions: 
• When we use an array statement, we assume the missing date to be the end of the 
year 2006 and also we convert it into a SAS date. 
• If the drug is continued during the survi val time, then it is censored and the value 
of STATUS is 0; otherwise, the value of STATUS is 1. 
• If CHMED is equal to the drug, it means the drug is switched to another drug; in 
other words, it is not censored. 
• Due to a lack of information, we set the start date equal to the beginning of the 
year 2006 and the end date to the end of the year 2006 if such information is 
unknown. 
• We also define the value of STATUS as 0 when the survival time DAYS is equal 
to 364. 
• We suppose the frequency of prescription for the year 2005 is at most 12. 
The SAS code [26] is shown below. 
DATA SASUSER.T06; SET SASUSER.MERGEDATA06; 
ARRAY MEDS(3) MED_l - MED_3; ARRAY DATES(3) DATE 1 -
DATE_3; 
DO J=l TO 3; IF DATES(J)=. THEN DATE='31DEC2006'D; END; 
DO 1=1 TO 3; 
IF 1=1 THEN TEMP=MEDS(I); 
IF MEDS(I) NE TEMP THEN DO; 
MED_NUM=I; DATE_NUM=DATES(I); CHMED=MEDS(I); 
STATUS=I; 1=3; 
END; 
END; 
/*Define 0-1 indicators and status*/ 
IF CHMED=' , THEN STATUS=I; 
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7 
8 
9 
10 
IF CHMED= , GLYBURIDE , THEN GLYBURIDE=O AND STATUS=l ; ELSE 
GLYBURIDE=l ; ... 
/*Define the variables days*/ 
IF DATE lA= . THEN SDATE=DATE_l ; ELS E SDATE= ' OlJAN2006 ' D; 
I F DATE 2A=. THEN EDATE=DATE_2 ; ELSE EDATE= ' 31DEC2006 ' D; 
FORMAT SDATE EDATE DATE9 ; DAYS=DATDIF 
(SDATE,EDATE, ' ACT/ACT '); 
IF DAYS=364 THEN STATUS=O; RUN ; 
Finally, we sort the new data by CHMED to get the data shown in Figure 7.14. 
O1JAN2Cffi 3&1 
O1JAN2Cffi 31DEC2Ol 3&1 
270EC2Cffi 270EC2Oll 
O1JAN2Cffi 31DEC21lli 3&1 
2O.IAN21X6 310EC2006 345 
1 01JAN2006 310EC2006 3&1 
1 OlFEB2OOl 31DEC2006 333 
1 3lWJG2OIll 310EC2006 123 
1: O1JAN2!ll 31DEC2006 3&1 
Figure 7.14. Survival Data for 2006 
In 2005, in order to get an accurate conclusion, we filter out the beneficiaries in 
the office-based visits file rather than in the prescription drug file. We first sort out the 
enrollees whose Medicare payments are greater than 0 according to the ICD 9 diagnosis 
codes. Then we get the results shown in Figure 7.15; and we use the same method to get 
another data set about diabetes patients in the outpatient visit file . 
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DUPERSID OBICD1X OBICD2X OBICDJ)( OBICD4X 
1 30078019 250 -1 -1 -1 
2 30121012 401 250 ; 185 530 
3 30180024 250 -1 -1 -1 . ,. ···+-1 . .... ,.-. ............ .- 30192012 250 -1 -1 
-- ................. 
5 30201026 250 -1 -1 -1 
6 30206025 250 401 -1 -1 
7 30363015 401 250 272 716 
8 30392041 250 -1 -1 -1 
9 30450010 590 429 250 -1 
10 3049401 3 401 250 716 530 ... " ................... . ............ " ........ ............... ... - " . . ....... ......... 
Figure 7.15. Diabetes Patients in Office-based Visit 
Finally, we use the SQL horizontal join to get all the diabetes beneficiaries and 
we use these patient IDs to find all Medicare drug plan enrollees. For analysis, we use the 
life table method, setting the interval at 10 days and stratifying the data by CHMED. The 
SAS code and some results are shown below. 
PRoe LIFETEST DATA=SASUSER. ST06 OUTSURV=SASUS ER . GP06 
ALPHA=O. 05 METHOD=LIFE WIDTH=10; 
TIME DAYS*S TATUS ( O); RUN ; 
STRATA CHMED; 
Table 7.5 Summary of CensoredlUncensored Values for 2005 
Summary of the Number of Censored and Uncensored Values 
Stratus CHMED Total Failed Censored Percent 
1 GLYBURIDE 4 4 0 0.00 
2 GL YBURIDE_METF 4 0 4 100.00 
3 INSULIN 8 3 5 62.50 
4 METFORMIN 90 10 80 88.89 
5 PRECOSE 3 1 2 66.67 
6 ROSIGLIT AZONE I 0 I 100.00 
7 TOLAZAMIDE 2 0 2 100.00 
Total 112 18 94 83 .93 
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Table 7.6 Summary of CensoredlUncensored Values for 2006 
Summary of the Number of Censored and Uncensored Values 
Stratu CHMED Total Failed Censored Percent 
1 GLYBURIDE 2 0 2 100.00 
2 INSULIN 7 0 7 100.00 
3 METFORMIN 100 17 83 83.00 
------------ -------
4 PIOGLIT AZONE 2 2 0 0.00 
5 PRANDIN I I 0 0.00 
6 PRECOSE 5 2 3 60.00 
7 STARLIX 3 I 2 66.67 
Total 120 23 97 80.83 
Results in Tables 7.5 and 7.6 show that the medications are divided into 7 groups 
in each year by CHMED. In 2005, since the number of prescriptions of rosiglitazone is 
one, we do not include it. The censored percentages of glyburide- metformin and 
tolazamide are 100 %, which means that it is hard for the patients to change such 
medicines once they begin taking them. In 2006, we also discard prandin due to one-time 
use. The censored rates of glyburide and insulin are 100 %, and the rate of metformin use 
is 83 %; all of these outcomes demonstrate that the three drugs can seldom be replaced by 
other medicines. In summary, the metformin and insulin uses are stable in both years. 
Glyburide itself is unstable in 2005, but stable in 2006. Moreover, the average censored 
rate in 2005 is a little higher than that in 2006, indicating that the usage of prescribed 
drugs is more stable in 2005. 
Next, we estimate the differences of survival cases among various drugs by 
survival functions. The survival distribution function (SDF) in 2005 (displayed in Figure 
7.16) demonstrates that none of the drug, tolazamide, is switched to the other medicines 
throughout the whole year. The survival rate of metformin decreases little by little from 
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100 % to 89 % at the end of the year. Ouring the three periods, 30th - 40th, 120th - 130th 
and 280th - 290th days, the prescriptions of insulin largely decrease, but in the other time 
periods, they remain unchanged. The sharp decrease of precose use appears between the 
190th day and the 200th day, but before and after that period, the usage is stable. A large 
number of beneficiaries switch their drugs from glyburide to the other medicines during 
the following periods, the 40th day - 50th day, the 90th - 100th day and 1 10th - 1 20th day, 
which means that the survival rate of the drug decreases to 20 percent at the end of the 
year. Therefore, the glyburide usage is very unstable in 2005. The SOF in 2006 (shown in 
Figure 7.17) shows that insulin and metformin survive longer than the other drugs since 
the survival rates are higher than that of any other drug throughout the year. None of 
prescriptions of insulin are changed to another medicine until the end of the year. Only 
less than 14 % of the prescriptions of metformin are switched to other drugs. Between the 
90th day and the 11 Oth day, large quantities of prescriptions of pioglitazone are changed to 
other drugs; however, after that, no more changes happen. The survival rate of precose 
goes down to 80 % around the 220th day, to 60 percent around the 280th day and then 
remains unchanged until the end of the year. The survival rate of starlix sharply decreases 
on the 320th day and then stabilizes. In general, metformin and insulin uses are more 
stable than those of the other medicines. 
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7.3 Effects of Drug Plan on the Cost Effectiveness of Medications and Health 
Outcomes 
The purpose of this section is to estimate the cost effectiveness of diabetes 
medications and the health outcomes in Medicare in 2005 and 2006 to examine the 
impact of Medicare, Part 0 using the data sets from MEPS [191. 
7.3.1 Cost Effectiveness Analysis 
First, we need to discover our research subjects who are Medicare drug plan 
enrollees in 2006 and also joined Medicare in 2005. To keep consistency, we do not 
consider the Medicare beneficiaries of age 65 in 2006; we also do not consider the 
patients who switch their drugs from the year 2005 to the year 2006. We use SAS SQL 
conditional selection to sort out the patients with diabetes according to the ICD9 
condition code. Then we use an SQL inner join to combine the full year consolidated data 
file and prescription drug file by the 10 variable, DUPERSID. After we find out the 
beneficiaries who joined in Medicare, Part 0, we use the DUPERSID to match the 
patients in 2005. Then we get a dataset that we need. After importing a life table, we can 
combine it with the newly-generated data and calculate ICERI displayed in Figure 7.18 
with the code shown below. 
/*Combine the life table and 2006 Medicare part 0 
beneficiary table */ 
PROC SQL; 
CREATE TABLE SASUSER.LE06 AS 
SELECT * 
FROM SASUSER.LIFETABLEI AS LT, 
SASUSER.BCHWLQ06 AS BC 
WHERE LT.AGE=BC.AGE06X; QUIT; 
/*Calculate the 2006 QALY for different genders*/ 
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2 
3 
4 
5 
6 
7 
8 
9 
10 
DATA SASUSER . QALY06 ; SET SASUSER . LE06 ; 
IF SEX=l THE N QALY06=MALE*LQ06; 
I F SEX=2 THEN QALY06=FEMALE*LQ06i RUN; 
PROC SORT DATA=SASUSER. QALY06 ; BY DUPERSID ; RUN ; 
/*To calculate t h e ICER */ 
PROC SQL ; CREATE TABLE SASUSER. CICER AS 
SELECT DUPERSID , SRXNAME, QALY05 , QALY0 6 , TOTMCR05 , TOTMCR06 , 
((TOTMCR06 - TOTMCROS) / (QALY06-QALYOS)) AS ICERl 
FROM SASUSER . ICER ; QUIT ; 
leER1 
·330223.68 
30136026 GliPIZIDE 6.8 9.768 0 11084 3734.50135 
30180024 GLYBURIDE 4.42 4.184 6974 1947 21300.8475 
30363015 GliPIZIDE 3.956 3.736 710 4578 ·1 7581.818 
30386013 GliPIZIDE 8.934 11376 0 1782 729.72973 
30392041 GLYBURIDE 2.71 5.164 2120 6140 1638.141 81 
30437028 GLY8URIDE 1.336 4.008 224 2434 827.095808 
·i 
30489011 STARLIX 11 .024 7.86 0 3952 ·1249.0518 
30507010 GLYBURIDE_M . 5.788 5.51 2 149 783 ·2297.1014 
30516018 GLYBURIDE 7.888 7.576 179 2737 ·8198.7179 
Figure 7.18. leER Table 
Table 7.7 leER by Different Diabetes Drugs 
SRXNAME Mean N 
GLIMEPIRIDE -1268.78 4 
GLIPIZIDE -12573.77 49 
GLYBURIDE -4728.05 45 
GL YBURIDE_METFORMIN 1934.47 10 
INSULIN -14203.62 16 
METFORMIN 896.1215818 44 
STARLIX -590.0887749 3 
Once we get the table, we use the proc means procedure in base SAS to get the 
average leER value for each drug shown in Table 7.7. Here, a negative leER means that 
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there are savings for the year 2006 over the year 2005. For example, the comparison 
between the year 2006 and the year 2005 for insulin treatment shows a cost saving of 
$14,203.62 in 2006. For a positive ICER, the bigger the ICER, the less efficient the new 
method. Therefore, Table7.7 demonstrates that insulin becomes the most cost-effective in 
2006, while Glyburide-metformin is the most inefficient treatment, and metformin is a 
close second. 
7.3.2 Medical Resources Utilization 
Next, we evaluate utilizations of healthcare resources by comparing the 
frequencies of office-based visits, outpatient visits and times of prescription drugs filled 
as well as the length of stay in the hospital or home health providers separately. We 
firstly find the data containing the times of office-based visits in these two years, then we 
use the times of visits in 2005 as the denominator; the difference of the times in these two 
years is used as numerator to calculate the increasing or decreasing rate. Finally, we get 
the average rates for each drug. In the same way, we also get the increasing and 
decreasing rates in the other cases. 
Table 7.8 shows that compared to the year 2005, the Medicare diabetes patients 
receive more drug treatments in 2006 since the drug refill rates increase by an amount 
varying from 17% to 66%. At the same time, the average LOS (length of stay) in the 
hospital of the insulin or glipizide users is largely decreased by 80% or 61 %, which 
means that adequate insulin or glipizide usage saves considerable hospitalization 
resources. However, the average of the prescription frequency and LOS of metformin 
users increases by 73% and 200 % respectively from the year 2005 to the year 2006. It is 
also true for glyburide users. In other words, the drug plan makes these two drug 
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treatments more inefficient. The relationship between the LOS in the hospital and the 
home health provider for most drug users is negative; the longer the stay using home 
health providers, the shorter the stay in the hospital. Considering the costs of 
hospitalization are higher than those of home health providers, the patients should 
sufficiently utilize the home health agency services. 
Table 7.8 Ratios in Utilizations of Healthcare Resources 
SRXNAME OBTRATIO OPTRATIO RXTRATIO LOS RATIO HHDRATO 
GLIMEPIRIDE 0.03 0 0.66 
GLIPIZIDE 0.52 0.19 0.22 -0.61 0.50 
-- -----------
GLYBURIDE 1.30 0.82 0.33 0.65 -0.01 
GLYBURIDE -0.12 0.80 0.20 -\.0 
METFORMIN - I 
-- -- -------r-- -------
INSULIN 0.01 -0.29 0.17 -0.8 -0.07 
METFORMIN 0.54 0.29 0.73 
i 
2.0 -0.40 
i 
STARLIX 0.61 0.45 
7.3.3 Health Status 
Finally, we use the decision tree model to investigate which factors have vital 
effects on the beneficiaries' health status. We input all the variables, frequencies of 
physician visits, drug prescriptions, Al C tests, ER (Emergency Room), LOS in the 
hospital or home healthcare agency, gender, age and family size. We set the health status 
as a predicted target. Figure7 .19 demonstrates that in 2005, the frequency of Al C tests 
and the physician visits have vital effects on a patients' health. Figure 7.20 indicates that 
in 2006, the frequency of drugs filled becomes a key factor to the patient's health 
status. However, there is something in common between these two years. LOS in the 
hospital and family size are not important factors to health conditions. 
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7.4 Conclusion 
Based on the analyses in Section 7.2, we can draw the conclusion that Medicare, 
part D indeed greatly increases the expenditures of Medicare on diabetes medications. 
The prescription drug plan itself reduces the choices of the medicines for diabetes for 
each year. We also discover that generally, the usage of insulin and metformin is always 
more stable than that of other drugs. However, glyburide usage is very unstable in 2005 
but stable in 2006. In addition, more drugs are switched into other medicines in 2006, 
which indicates that the use of drugs is less stable than that in 2005. It is also discovered 
that in 2005, female patients spend more on insulin and supplies, while the males spend 
more on metformin. In 2006, the female beneficiaries pay more for metformin. 
Cost-effectiveness analysis suggests that Medicare, Part D makes the insulin 
treatment the most efficient, while the combination of glyburide - metformin is the least 
effective. Our results also demonstrate that under this drug plan, the Medicare 
beneficiaries can receive more sufficient drug treatments than ever before. In the 
meanwhile, enough usage of some drugs such as insulin can decrease the usage of 
hospital resources. In contrast, the metformin users stay in the hospital for a longer time 
in 2006. Another discovery is that using the drugs properly can improve the patient health 
status. 
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CHAPTER VIII 
CONCLUSION 
In this dissertation, we introduced pattern recognition analysis and supervised! 
unsupervised machine learning algorithms as well various kinds of linear statistical 
models into the study of diabetes patients in the Medicare population and we proposed 
several methods to decrease Medicare expenditures while improving healthcare quality. 
First, we utilized the linear statistical models to complete a cost analysis of 
diabetes outpatients in Medicare. We conclude that most predictors that we find are key 
factors influencing the costs and we suggest that outpatients with diabetes should often 
monitor their blood glucose level and the patients with such complications as anemia and 
heart diseases need more medical care. By these means, the costs can be decreased to 
some extent. 
Second, we applied supervised learning approaches such as the decision tree 
model and market basket analysis to an outcomes study of inpatients. We arrive at the 
conclusions that the patients who have procedures related to heart diseases often need 
other procedures; neither age nor the end-stage renal disease is the key factor to mortality, 
which is contrary to widely held belief. 
Third, we employed pattern recognition analysis and the decision tree model in 
readmission risk analysis. Patients with cardiovascular or kidney co-morbidities have a 
higher risk of readmission than those with other diseases. Another discovery is that the 
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patients without professional medical services are more likely to be readmitted to the 
hospitals after discharge. 
Fourth, we performed two- way interaction effects analysis using the generalized 
linear model with a gamma distribution, the logistic regression model and the Poisson 
regression model. We find that as for inpatients expenditures, most two -way interaction 
effects between diabetes complications are significant; when the response variable is 
frequency of hospitalization, only the effects between kidney disease and the other 
diseases are significant to the Poisson regression model. We also conclude that the 
patients who have both heart disease and kidney disease have a much higher risk of dying 
since the interaction effect between these two diseases are significant to mortality in the 
logistic regression model. 
Fifth, we used survival analysis to analyze diabetes drug usage. Results 
demonstrate that insulin and metformin are more stable than other drugs in terms of usage 
and the uses of drugs in 2005 are more stable than those in 2006 with the influence of 
Medicare, Part D. 
Finally, we applied cost-effectiveness analysis to diabetes medications. The 
results indicate that with the introduction of the Medicare drug plan, insulin becomes the 
most cost-effective treatment and the combination of glyburide and metformin is the most 
inefficient. They also demonstrate that metformin users highly increase their length of 
hospitalization and the frequency of prescriptions from the year 2005 to the year 2006. 
In summary, in this dissertation, several new algorithms and methods are 
introduced or improved and some suggestions are proposed to decrease Medicare costs 
and improve health outcomes. 
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